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ABBREVIATIONS 
ABC Ammonium bicarbonate 
ABPP Activity-based protein profiling 
ACC 7-amino-4-carbamoylmethylcoumarin 
ACE Acetylcholinesterase 
ACN Acetonitrile 
AEBSF 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride 
AMC Asp-7-amino-4-methyl-coumin 
BCA Bicinchoninic acid 
BSA Bovine serum albumin 
CHCA Α-cyano-4-hydroxycinnamic acid 
CMC Carboxymethyl Cellulose 
CV Coefficient of variation 
ddH2O Ultra-pure water 
DHB 2,5-dihydroxybenzoic acid 
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ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
ESI Electrospray ionisation 
EtOH Ethanol 
FA Formic acid 
FFPE Formalin-fixed paraffin-embedded 
FRET Fluorescence resonance energy transfer 
FT-ICR Fourier Transform Ion Cyclotron Resonance 
FWHM Full-width half maximum 
GIST Gastrointestinal stromal tumour 
H&E Hematoxylin & Eosin 
HC Hierarchical clustering 
HCl Hydrochloric acid 
IQR Inter-quartile-range 
ITO Indium Tin Oxide 
LC-MS/MS Liquid Chromatography-Tandem Mass Spectrometry 
LFQ Label-free quantification 
m/z Mass to Charge 
MAD Mean absolute deviation 
MALDI  Matrix-assisted laser desorption/ionization  
MeOH Methanol 
MMP Matrix metalloprotease 
MRI Magnetic Resonance Imaging 
MS Mass Spectrometry 
MSI  Mass Spectrometry Imaging 
NIR Near-infrared 
ON Overnight 
PBS Phosphate buffered saline 
PCA Principal Component Analysis 
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PET Positron emission tomography 
PIM Protease-inhibitor mixture 
qPCR Quantitative polymerase-chain reaction 
RG RapiGest SF Surfactant 
ROI Region of interest 
RT Room temperature 
S/N Signal-to-Noise ratio 
SDS Sodium dodecyl sulfate 
SOP Standard operating procedure 
TCA Trichloroacetic acid 
TCEA-
positive 
CEA424-SV40TAg transgenic mice (C57BL6 background) with 
developed tumour  
TCEP Tris(2-carboxyethyl)phosphine 
TFA Trifluoroacetic acid 
TGGA The cancer genome atlas 
TIC Total Ion Current 
TIMP Tissue matrix metalloprotease inhibitor 
TOF Time of Flight 
TPAA Tissue protease activity assay 
WHO World health organisation 
WT Wild-Type 
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1 INTRODUCTION 
1.1 Classification of Proteases 
The enzyme class ‘hydrolases’ and their subclass ‘peptidases’ (EC 3.4.-.-), defined by 
the Enzyme Commission in 1961, comprise any enzyme that hydrolyzes peptide bonds 
(synonyms: peptide hydrolase, protease, proteinase)1,2. The class is further divided 
into ‘exopeptidases’, which act at the terminus of the substrate’s polypeptide chain and 
‘endopeptidases’ that act internally in the polypeptide chain. Several sub-subclasses 
are defined, for example for exopeptidases: aminopeptidases (EC 3.4.11.-) that 
liberate a single amino acid at the N-terminus or dipeptidyl-peptidases and tripeptidyl-
peptidases liberating two and three amino acids, respectively (EC 3.4.14.-). 
Furthermore, endopeptidases are divided into sub-subclasses based on their ) catalytic 
mechanisms (e.g. metalloproteases, serine- or cysteine proteases Table 1). The 
human degradome (the complete set of proteases) comprises in total 569 proteases, 
whereas the rat and mouse degradome seem to consist of even more proteases (644 
and 629, respectively)3. Serine-type, cysteine-type and metallo carboxypeptidases (EC 
3.4.16, EC 3.4.18 and EC 3.4.17, respectively) cleave with a similar catalytic 
mechanism but act on the C-terminus of the polypeptide chain liberating a single 
residue. 
Based on two fundamental differences mammalian proteases can be separated in the 
catalytic mechanisms. Serine-, cysteine- and threonine-proteases perform covalent 
catalysis, where the nucleophile of the catalytic site is part of an amino acid. The 
amino acid histidine thereby works commonly as the base in the active centre. In 
contrast, metallo- and aspartic proteases use non-covalent catalysis, and an 
activated water molecule is the nucleophile. Here aspartate or glutamate residues 
serve as bases (as deprotonated acid, it takes the proton of the water molecule) for 
the catalytic mechanism. For metalloproteases, a coordinated zinc molecule polarizes 
the carbonyl group of the substrate, while it facilitates the deprotonation of the water 
molecule. The specificity of each protease is used to identify the single enzyme of each 
sub-subclass not being defined solely by the nature of the catalytic centre. The binding 
sites, surrounding the catalytic centre, favour specific amino acids and therefore 
ensure proteolytic activity when required4. With that mechanism, proteases display a 
high degree of specificity. 
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Table 1: Sub-subclasses of endopeptidases with their respective enzyme commission number 
Sub-subclass EC 
Residue and 
molecule responsible 
for initiating cleavage 
of the peptide bond 
Number of 
proteases in 
human 
degradome3 
MEROPS 
database 
identifier 
Serine endopeptidase 
EC 
3.4.21.- 
Hydroxyl group of 
serine 
176 S 
Cysteine 
endopeptidase 
EC 
3.4.22.- 
Thiol group of cysteine 150 C 
Aspartic 
endopeptidase 
EC 
3.4.23.- 
Carboxyl group of two 
aspartates 
21 A 
Metalloendopeptidase 
EC 
3.4.24.- 
Zinc ion bound in the 
active centre 
194 M 
Threonine 
endopeptidase 
EC 
3.4.25.- 
Hydroxyl group of 
threonine 
28 T 
 
In the case of trypsin, a well-known serine-protease (EC 3.4.21.4) found in the 
mammalian digestive system, the bindingsites target positively charged amino acids. 
Therefore cleavage only occurs, when a lysine (Lys, K) or arginine (Arg, R) is attached 
to the binding site. A following proline (Pro, P) disturbs the interaction and impedes the 
cleavage process. The hydrolysis of the peptide bond is irreversible, because, on the 
one hand, the reaction equilibrium favours two amino acids, on the other hand, there 
is no enzyme counterpart to repair already cleaved proteins. As no turn-back process 
is implemented in biological processes, proteases should only be active when needed. 
In order to achieve this, they are expressed as zymogens (inactive precursors) and 
activated when needed by complex signalling cascades to ensure target amplification 
of the desired biological effect5–7. The group of matrix metalloproteases (MMPs) is 
further controlled by tissue matrix metalloprotease inhibitors (TIMPs), which together 
with hormones, cytokines and growth factors regulate their expression8.  
Initially, the role of protein degradation was attributed to food digestion and intracellular 
protein turnover9. Nowadays it is known, that proteolysis is related to key physiological 
processes like blood clotting, cell-cell progression, cell proliferation, cell death, DNA 
replication, tissue remodelling, and immune response10. 
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1.1.1 The role of proteases in disease 
A gain-of-function and loss-of-function of proteases result in several pathological 
conditions, such as cardiovascular-11, inflammatory-12, neurodegenerative-13, infective 
diseases14 as well as cancer3.  
With cancer intracellular and extracellular proteases are associated with tumour 
growth, survival, angiogenesis, invasion, inflammation, and metastasis15,16. It has been 
shown, that intracellular Caspases, which play a fundamental role in apoptosis, are 
related to tumour growth17,18. By degrading extracellular components Cathepsins allow 
tumour cells to invade surrounding tissue, blood and lymph vessels19,20. Trypsin, as 
another example, is involved in proliferation, invasion, and metastasis of colorectal 
cancer21. Furthermore, MMPs are released by tumour cells and tumour-surrounding 
stromal cells, and also degrade ECM to enable invasive tumour growth22–24. 
Deubiquitylases, Autophagins, ADAMTSs (short term for a disintegrin and 
metalloproteinase with thrombospondin motifs), Neprilysin, Kallikreins, and other 
proteases are also involved in tumour progression3. It is thus of great importance to 
know the molecular mechanism of proteases. For this reason, the MEROPS – the 
peptidase databasea was developed, where known proteases, their related substrates, 
and inhibitors are listed25. An additional MEROPS identifier was developed, which 
indicates the catalytic type directly26 (Table 1). Additional information is summed up in 
the Degradome databaseb, that comprises mammalian proteases and their associated 
diseases27. Whole genomic sequences from multiple organisms (human, chimpanzee, 
mouse, and rat), genetic diseases, protease structures, and protease inhibitors are 
implemented. 
 
Excessive proteolysis can be reduced by therapeutic inhibitors, which are therefore 
widely investigated by pharmaceutical companies14,28. The development of 
angiotensin-converting enzyme (ACE) inhibitors used to treat hypertension, heart 
failure, and heart attack was a major success. About 20 different inhibitors (e.g. 
Captopril – Bristol-Myers Squibb, Lisinopril - AstraZeneca, Cilazapril – Roche) 
successfully target ACE, a metalloprotease of the renin-angiotensin system. In 
contrast, all MMP inhibitors combating cancer (e.g. marimastat – British Biotech, 
                                            
a http://merops.sanger.ac.uk 
b http://degradome.uniovi.es 
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prinomastat – Aguron or neovastat – Aeterba) failed in clinical trials due to severe side 
effects or lack of clinical benefit. Reasons for this are the fact that most inhibitors 
targeted broad-spectrum MMPs, and little was known about the diversity of MMPs. 
Secondly, the inhibitors seem ineffective against late-stage tumours (of the patients) 
but showed an effect in early stage tumour models14. 
1.1.2 Relevant proteases in gastric cancer 
Gastric cancer used to be the leading cause of cancer deaths worldwide. It is separated 
anatomically into gastric adenocarcinomas (non-cardia) and gastro-esophageal-
junction adenocarcinomas (cardia). Although most gastric cancers are gastric 
adenocarcinomas, the variety in architecture and growth, cell differentiation, 
histogenesis, and pathogenesis is high29. According to Lauren classification, four 
histological types are defined: diffuse (poorly differentiated, solitary tumour), intestinal 
(well differentiated, glandular structures), mixed and indeterminate30. A WHO 
classification comprises five histological classifications (tubular, papillary, mucinous, 
poorly cohesive, rare variants). The most commonly used system is the American Joint 
Committee on Cancer TNM (tumour, node, metastasis) staging31.  
 
In order to complement the preexisting classification based on histopathologic and 
anatomic criteria molecular and genetic findings were added. In a training set for 
supervised classification of 36 patients with localized gastric cancer three subtypes 
(proximal non-diffuse, diffuse, and distal non-diffuse) Shah et al. identified different 
gene expression patterns in >85 % of the samples32. Further, excessive studies have 
been performed to classify gastric cancer on a molecular level. Lei et al. compared the 
gene expression pattern of 248 gastric tumours and found three major subtypes: The 
proliferative subtype showed a high number of TP53 mutations (Tumour-suppressor 
gene 52; involved in regulation of apoptosis and DNA repair mechanism) and was 
grouped to the Lauren diffuse gastric cancer type. The mesenchymal subtype 
showed low TP53 mutations and a low level of CDH1 (gene for the protein E-Cadherin 
and also a tumour suppressor gene). This group had a histologic correlation to the 
Lauren diffuse type. The third group was named metabolic subtype having also low 
TD53 mutation and was more sensitive to 5-fluorouracil (5-FU, a cytotoxic agent used 
in chemotherapy)33. As part of The Cancer Genome Atlas (TCGA), 295 gastric 
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adenocarcinomas were analyzed and a new classification in four subgroups on a 
molecular basis was proposed34: 
1. Tumour positive for Epstein-Barr virus (EBV) 
2. Microsatellite unstable tumours (MSI) 
3. Genomically stable tumours (GS) 
4. Chromosomally unstable tumours (CIN) 
 
The EBV is a pathogen that is associated with gastric cancer since 199035. The virus 
disrupts the genes responsible for cell cycle regulation, inflammation, and 
angiogenesis. Microbial infections with the Helicobacter pylori (H. pylori) also 
contribute to gastric tumorgenesis36. Microsatellite instability is due to repetitive DNA 
sequences and is a result of impaired DNA mismatch repair, such as single base 
mismatches, short insertions, and deletions. The authors saw this new classification 
as an additive to histopathology, while there certainly exists some differences between 
those disciplines. Clinical trials with target therapies for distinct populations of gastric 
cancer patients are required.  
In 1990 the comparison of homogenates from gastric cancer tissue and normal gastric 
tissue showed differences in cathepsin B, cathepsin L, tissue plasminogen activator (t-
PA) and urinary plasminogen activator (u-PA). These differences seemed to favour 
cancer invasion and metastasis37. In a study of 301 gastric cancer patients the loss of 
expression of caspase-1 correlated with poor patient survival in gastric cancer38. 
Further reduced caspase-2 expression was found as an indicative marker for early-
stage gastric carcinogenesis39. The expression of Hepsin, a transmembrane serine 
protease, was shown to be downregulated in gastric cancer tissue, whereas high 
expression of Hepsin correlated with a poorer survival40. Allgayer et al. showed that it 
is possible to identify high-risk protease pattern (proteases/inhibitor systems): 
Cathepsin D, α-1-antichymotrypsin, α-1-antitrypsin and α-2-macroglobulin had a 
prognostic impact on gastric cancer and indicated high individual risk. Furthermore, 
Cathepsin D seemed to be a parameter for disease-free survival41. Highly sensitive 
methods are required in order to detect early gastric cancer. Labisso et al. showed that 
Cathepsins and MMPs were potential biomarkers for early gastric cancer. During the 
conventional endoscopic examination of the upper gastrointestinal tract, early gastric 
cancer is often missed. The use of imaging modalities, like specific probes with 
fluorophores, could help to overcome this obstacle42.   
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1.2 Visualization of protease activity 
Apart from the analysis of gene expression levels, where the sample preparation 
requires homogenization of the tissue, “smart” imaging reagents and optical 
instrumentation are used. Monitoring of enzymatic activity in the context of intact cells 
(in vitro) or even in whole organisms (in vivo) is possible with those reagents. In 1997 
a substrate library (PS-SCL = Positional scanning substrate combinatorial library) to 
study protease preferences with the fluorophore Asp-7-amino-4-methyl-coumarin 
(AMC) was developed43. The fluorophore 7-amino-4-carbamoyl-methylcoumarin 
(ACC) which was applied in the same library, improved the method for protease 
substrate specificity investigation44. Fluorescent probes are designed based on the 
substrate of the protease of interest and carry a fluorophore. So after enzymatic 
conversion and excitation in the lower UV/VIS range, the emission spectrum with its 
maximum shifted to higher UV/VIS wavelength is measured.  
 
 
Figure 1: Probe designs to monitor protease activity A Initially quenched fluorophore is released after 
cleavage and emits photons B Fluorophore substrate emits photons when released C Quenched activity-based 
probe emits fluorescence after cleavage of the substrate D Activity-based probe tagged with a fluorophore 
attached to the target active centre of the enzyme. The figure is used with permission of John Wiley and Sons 
from Kasperkiewicz et al.45 (License Number 4502511000947). 
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Figure 1 shows different designs of fluorescent substrates that emit characteristic 
photons after un-quenching or activation by proteases. Activity-based protein profiling 
(ABPP) was developed to target proteins in their native form and thus target the 
functional state of the enzyme46,47. Active enzymes can be distinguished from their 
inactive zymogen or inhibited form with that mechanism48. ABPP probes modify the 
enzyme by forming specific covalent bonds with the catalytic residue.  
However, the reporter lacks in specificity, cell permeability, and rapid diffusion. The 
main drawback is the autofluorescence of the cellular environment. To produce higher 
signal-to-noise ratios, protease-responsive near infrared (NIR) probes have been 
developed. Substrate-enzyme specificity allows some targeted analysis of the 
protease, but also requires detailed knowledge for the appropriate probe design. 
Challenges like high chemical and photo-stability, non-toxicity, biocompatibility, and 
biodegradability impede the probe design and need to be overcome. Although these 
probes are used in vitro and in vivo, direct visualization and investigation of protease 
activity in tissue sections remain underexplored49. Only Withana et al. topically applied 
fluorescence-quenched activity-based probes to fresh-frozen tissue sections which 
enabled visualization of protease activity at cellular resolution50. 
1.3 Mass Spectrometry 
About 100 years ago mass spectrometry (MS) began with J.J. Thomson and his 
discovery of the electron in 189751. An early stage mass spectrometer, called parabola 
spectrograph, was build and refined in 1919 into the first mass spectrometer by Francis 
W. Aston52. A. J. Dempster was the one who developed the first electron impact source 
to enable analysis of elements and small molecules. With the development of Fourier 
transform ion cyclotron resonance53(FT-ICR), magnetic sector double-focusing54, time-
of-flight (TOF)55,56, and quadrupole57 mass analysers the detectable mass range and 
resolution improved. To allow analysis of large and small-biomolecules the 
development of softer ionisation techniques like electrospray ionisation (ESI)58 and 
matrix-assisted laser desorption/ionisation (MALDI)59 was required. With less energy 
intake in the ion source fragmentation is reduced and the stability of the ionised 
molecules is improved. 
In mass spectrometry chemical species (being elements or molecules) are ionised in 
the ion source, separated by their mass-to-charge ratio (m/z) in the mass analyser, 
and recorded in a detector system according to their relative abundance. The 
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developed systems are as different as chemical species can be. For biomolecules, soft 
ionization techniques and mass analyser with a high mass range are required to cover 
the biological diversity (i.e. lipids, peptides and proteins ranging up to several 100kDa). 
That is why MALDI and TOF-MS or FT-ICR-MS are often combined in order to analyse 
complex biological matrices.  
1.3.1 The principle of MALDI mass spectrometry 
MALDI MS requires the application of a matrix solution onto the sample or the matrix 
solution is mixed with a sample solution. During evaporation of the matrix solvent, the 
sample’s analytes co-crystallise with the matrix forming a layer of analyte-matrix-
crystals. Which molecules co-crystallise is dependent on their physicochemical 
properties and the properties of the used matrix. Some matrices prioritise smaller, other 
larger molecules60. The formation of crystal size is different for different matrices. The 
ions required for the separation in the mass analyser are generated by radiation with 
a pulsed focused laser beam (commonly neodymium-doped yttrium aluminium garnet 
(Nd:YAG) laser with a wavelength of 355 nm). 
1.3.2 MALDI MS Imaging 
In 1997 Caprioli et al. introduced MALDI MS as a method for mass spectrometry 
imaging (MSI) in order to combine classical tissue proteomics and histology61. It can 
help in therapeutic management and could confirm a diagnosis. In addition, MSI as a 
tool to discover new biomarkers can give semi-quantitative mapping information and 
can be used to evaluate tissue heterogeneity and complexity, where classical 
molecular pathological methods fail. For clinical research pathology tissues are the 
manifestation of many diseases, and morphological or molecular features are of great 
importance. The understanding of the molecular basis of diseases in particular, leads 
to insights into their mechanism and changes in tissue morphology62. Mass 
spectrometry combines the advantages of high sensitivity, molecular specificity, and 
detection of several classes of molecules (proteins, peptides, lipids, drugs and 
metabolites), thus providing unique insight into biological systems. As MALDI is a soft 
ionization technique, the analysis of a wide range of molecules is possible (100 Da – 
30 kDa). In addition, MALDI predominantly produces singly charged molecules which 
makes interpretation of complex mixtures easier. The use of laser ionization allows the 
analysis of specific histologically relevant tissue regions and can be analysed in a pixel-
to-pixel distance of 100 µm down to subcellular range63.  
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To generate a MALDI MS image the matrix is applied onto the tissue in a homogeneous 
layer. Laser radiation is performed in a raster over the whole tissue, and mass spectra 
are generated for each x-y-position (Figure 5). As the laser permeates only the crystal 
layer on the tissue, the integrity of the tissue is preserved and histological staining after 
MALDI MS measurement is possible. 
 
 
Figure 2: Principle of MALDI mass spectrometry imaging A clinically relevant tissue section is coated with a 
MALDI matrix. The solvent of the matrix extracts molecules from the tissue which then co-crystallize with the 
matrix molecules. In a raster process, the tissue is measured so, that at each position a laser shoots and ionizes 
the co-crystallized molecules, which are analysed in a time-of-flight (TOF) mass spectrometer. This results in 
mass spectra at each position of the measurement raster. The underlying tissue stays unaffected from the laser 
shots and can be histologically stained for histology-directed mass spectra. The figure is used with permission 
of Springer Nature from Aichler and Walch64 (License Number 4498730581944).  
 
1.3.3 The current method for tissue preservation 
MSI is typically performed on fresh-frozen tissue65, which is very rarely used as tissue 
preservation in a standardized manner for routine pathology. In contrast, formalin 
fixation and paraffin embedding (FFPE) preserves the morphology and cellular details 
and has thus become the standard preservation procedure66. The formaldehyde 
induces molecular changes in the form of cross-links between proteins, or between 
proteins and nucleic acids, with hydroxymethylene bridges. The coordinated bonds are 
responsible for the masking of epitopes and retaining the secondary structure of 
proteins. This process takes between 24 and 48 hours (until completeness66) and is 
not equalised for different hospitals, thus resulting into many observed variants in 
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immunohistochemistry (IHC) stainings67. After fixation in 10% neutral buffered formalin, 
the tissue is dehydrated in a series of grading alcohol concentration and then cleared 
in xylene. Finally, the tissue is embedded in paraffin.  
 
Storing the FFPE tissue blocks at RT saves maintenance, space and labour costs that 
are required for frozen tissue storage. Clinical pathology departments routinely store 
large numbers of FFPE blocks, which are an extensive repository of tissue material68. 
With antigen retrieval methods IHC on FFPE samples was facilitated69. Further, 
antigen retrieval was used to extract DNA; RNA and proteins from FFPE tissue70. With 
improved deparaffinization and antigen retrieval methods, FFPE tissue allowed 
proteomic experiments in mass spectrometry71,72. In the top-down proteomics 
approach the purified protein is analysed in its intact form using tandem mass 
spectrometry (MS/MS)73. Here no enzymatic digestion is required, as the intact protein 
is trapped in an Ion Trap, FT-ICR or Orbitrap mass analyser and is further fragmented 
by e.g. electron-capture dissociation (ECD). 100% sequence coverage and full 
characterisation of proteoform can theoretically be achieved with that method. The 
proteoform is defined by the molecular form of the protein resulting from genetic 
variation, alternative splicing, and post-translational modifications. Further top-down 
methods lack dynamic ranges as abundant species are dominantly fragmented. Thus 
complex mixtures were more often analysed by shotgun or bottom-up proteomic 
experiments74. In bottom-up approaches the protein mixture is purified using gel 
electrophoreses. Then it is enzymatically digested and the resulting peptides are 
analysed by MS and MS/MS75. Few top-down studies using MALDI MSI had been 
performed but were limited to proteins <9kDa76,77. When the whole tissue slice is used 
for digestion (reflecting a bottom-up approach), the whole tissue proteome is 
theoretically accessible. Maier et al. showed that with MALDI MSI only a subset of 
proteins, compared to classical proteomics, is incorporated in the matrix crystals and 
can thus by identified78. Nevertheless, on-tissue digestion combined with MSI revealed 
the localization of proteolytic peptides and enables identification in MS/MS79. 
1.3.4 On-tissue digestion for MALDI MSI 
In the last decade several researchers used on-tissue digestion for distribution analysis 
of proteolytic peptides. The preparative workflow is complex and requires multiple 
steps starting from dewaxing, heat-induced antigen retrieval, tissue digestion to MALDI 
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matrix embedding and MALDI MSI data acquisition (Figure 6). Additionally the 
published methods vary in analysed tissue specimen and used preservation technique. 
 
Fresh-frozen tissue requires washing steps (in graded ethanol) to reduce lipids and 
salts which interfere with the enzymatic digestion80. The removal of paraffin and 
antigen retrieval is necessary for FFPE tissue. Those washing steps differ in the 
application of the solvent (pipetting or beaker), the solvent itself (buffers), duration 
(several minutes) and temperature. It had recently been investigated that the thickness 
of the FFPE slice also had an influence the result81. The enzyme and the enzyme 
application system allows the location of peptides after MALDI MSI. Exemplarily, Table 
2 lists several publications with the used enzyme application systems, tissue specimen 
and preservation technique. The list does not cover all published methods, but 
emphasizes the diversity: The here listed methods use six different enzyme application 
systems ranging from microspotting to spray devices, with different application 
settings. On-tissue digestion has been performed on three preservation techniques: 
fresh-frozen (FF), FFPE and FFPE tissue microarrays (TMA). Tissue microarrays are 
paraffin blocks, where several hundred tissue cores (about 0.6 mm) are sorted in an 
array pattern82.  
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Table 2: Diversity of published instrumentation and material used for on-tissue digestion  
FIRST 
AUTHOR 
YEAR TISSUE SPECIMEN 
PRESERVATION 
TECHNIQUE 
ENZYME APPLICATION 
DEVICES 
GROSECLOSE 
et al.83 
2007 
brain and pituitary 
gland from rat 
FF 
microspotting chemical 
inkjet printer (chip-1000, 
Shimadzu biotech) 
STAUBER et 
al.84 
2008 rat brain slices FFPE 
microspotting chemical 
inkjet printer (chip-1000, 
Shimadzu biotech) 
RONCI et al.85 2008 
tissue surrogate, 
human breast 
cancer 
FFPE apply and drain solution 
GROSECLOSE 
et al. 86 
2008 
adenocarcinoma and 
squamous cell 
carcinoma 
FFPE (TMA) microspotting, portrait 630 
GRAVIUS et 
al.87 
2008 
human periprosthetic 
tissue 
FFPE 
spraying device ImagePrep 
(Bruker Daltonics) 
STAUBER et 
al.88 
2010 rat brain slices FF & FFPE 
microspotting chemical 
inkjet printer (chip-1000, 
Shimadzu biotech) 
GUSTAFSSON 
et al.89 
2010 
human ovarian 
cancer 
FFPE 
microspotting chemical 
inkjet printer (chip-1000, 
Shimadzu biotech) 
CASADONTE 
AND 
CAPRIOLI90 
2011 biopsies FFPE (TMA) microspotting (portrait 630) 
ENTHALER et 
al.91 
2012 
human skin from 
back and abdomen 
FF 
spraying device ImagePrep 
(Bruker Daltonics) 
POWERS et 
al.92 
2014 
human tissues, 
mouse kidney, liver 
cancer, prostate 
tumour 
FFPE (TMA) 
spraying device ImagePrep 
(Bruker Daltonics) 
DE SIO et al.93 2014 
human brain, kidney, 
thyroid, small bowel 
FFPE 
spraying device ImagePrep 
(Bruker Daltonics) 
CASADONTE 
et al.94 
2015 renal biopsies FFPE 
spraying device ImagePrep 
(Bruker Daltonics) 
HEIJS et al.95 2015 mouse brain FF 
spraying device SunCollect 
(SunChrom) 
DIEHL et al.96 2015 rat brain slices FF & FFPE 
spraying device ImagePrep 
(Bruker Daltonics) 
HOLST et al.97 2016 
leiomyosarcoma, 
colorectal carcinoma 
FFPE 
spraying device SunCollect 
(SunChrom) 
OETJEN et al.98 2016 rat brain FFPE 
spraying device ImagePrep 
(Bruker Daltonics) 
MASCINI et 
al.99 
2018 
oral squamous cell 
carcinoma, 
oropharyngeal 
squamous cell 
carcinoma 
FFPE (TMA) 
spraying device SunCollect 
(SunChrom) 
ANGEL et al.100 2018 
liver with 
hepatocellular 
carcinoma, 
colorectal cancer, 
aortic valve tissue, 
porcine heart 
FFPE 
spraying device TM-sprayer 
(HTX Technologies) 
(FF = fresh-frozen; FFPE = formalin-fixed paraffin-embedded) 
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After digestion the choice of MALDI matrix influences the visualized peptides by the 
sample type or the molecular weight of the co-crystallizing molecules. The matrix 
application system also affects the resolution of the image. Large matrix droplets can 
lead to diffusion of analytes and thus limit lateral resolution. Furthermore, the size of 
the matrix crystal (and so resolution) is influenced by the application system, solvent, 
additives (salts), and temperature. The matrix droplets are ideally big enough to ensure 
efficient analyte extraction from the tissue and small enough to reach a high spatial 
resolution.  
Resolving power R is defined as 𝑚 ∆𝑚⁄  where 𝑚 is the mass and ∆𝑚 the peak width, 
precisely the full width at half maximum (FWHM). It is an instrument property that 
describes the ability of the MS to distinguish two adjacent ions. High resolution mass 
spectrometers like FT-ICR MS can yield resolving powers of 1,000,000. The mass 
accuracy (or mass measurement error) can be calculated  by ∆𝑚𝑖 = (𝑚𝑖 − 𝑚𝑎) in Da 
or 
(𝑚𝑖−𝑚𝑎)
𝑚𝑎
𝑥 106 in ppm (parts per million), where 𝑚𝑖 is the mass of the individual 
measurement and 𝑚𝑎 is the accurate mass
101. In the case of MALDI-TOF MSI, the 
resolving power is 15,000 and mass accuracies of 0.1-0.01 Da are achieved102. FT-
ICR instruments give better mass resolution and accuracy, at the expense of (much 
longer) measuring time. According to the law of error propagation errors in such a multi-
step workflow multiply. The FFPE tissue preparation for MALDI MSI is therefore prone 
to high variability and requires an even more standardized protocol. For MALDI MS 
target measurements (in contrast to MALDI MSI experiments) reproducibility has 
already been a matter of interest. O’Rourke et al. stated that high throughput sample 
analysis with MALDI MS require robust and reproducible protocols103. This could be 
achieved by using nitrocellulose as it improves signal-to-noise, spot homogeneity, and 
reproducibility104,105. 
In a clinical context it has been suggested that on-tissue digestion of FFPE tissue can 
classify human pancreatic cancer106, prostate tumours107 and lymph node 
metastasis99. In another scenario the method is capable of successfully diagnosing 
amyloidosis, a disease with abnormal and accumulating protein folding resulting in 
harmful fibrils in tissue94. On-tissue digestion is also able to discover biomarkers by 
using hospital biopsy libraries as shown exemplarily for Parkinson disease84. 
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1.3.5 Data processing and statistical analysis in MALDI MSI 
For accurate and reliable results standardised data processing and interpretation is 
also necessary. The acquired spectra require preprocessing like baseline correction, 
noise removal, realignment and peak picking. Normalisation strategies are required to 
allow the comparison of different samples. Commercial software packages cover some 
of those steps and help investigate the distribution of specific ions of interest. As MSI 
produces very large datasets (several GB per tissue slice108,109), these software 
packages typically lack the ability of comparing several measurements in a multivariate 
statistical manner. In addition large datasets require long processing times. SCiLS Lab 
(SCiLS GmbH, Bremen) makes it possible to combine different measurements and 
perform basic statistics on them96,100, but it is restricted to the predefined tools. Open 
source mathematics packages (e.g. R, R Studio) provide statistical tools, which can be 
applied to MSI datasets by trained statisticians.  
 
In MALDI MSI the method development and validation has so far been rarely 
investigated. Diehl. et al. worked on the optimal preparation protocol for on-tissue 
digestion comparing different enzymes (Trypsin and LysC-Mix), digestion time and 
temperature, and MALDI matrices (DHB and HCCA)96. Using Principal Component 
Analysis (PCA) for mean and pixel-wise analysis they offered a recommendation of a 
standard operating protocol for FF and FFPE material. PCA is used to reduce the 
overall dimensionality of multidimensional data while the data variance is retained. 
Heijs et al. investigated the optimal digestion time (1.5h, 3h or 18h) by counting the 
picked peaks95. Later Oetjen et al. used fractional factorial design to find the optimal 
protocol for on-tissue digestion and proposed specific conditions regarding enzyme, 
incubation time and buffer system98.  
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2 AIMS 
Part (I) The current bioimaging methods for measuring active proteases focus on 
specifically designed tracer substrates that allow photometric monitoring of the activity 
of the targeted protease. Although these tracers can be used in vivo and in vitro, the 
synthesis of tracers that combine biocompatibility, specificity and photometric label is 
challenging. Mass spectrometry can be used label-free, as the measured m/z ratio is 
a physicochemical property of each molecule. MALDI MSI is an evolving technique 
combining the advantages of mass spectrometry and spatial resolution. It has already 
been shown that biomolecules like proteins, peptides, lipids, carbohydrates or glycans 
are detectable. So far it has not been explored whether MALDI MSI can be used for 
measuring protease activity in frozen tissue slices. Therefore part I of the present study 
had the following aims: 
(1) To develop a method using MALDI MSI for monitoring tissue protease activity 
exemplarily on different porcine tissues. 
(2) To validate the developed method by time- and concentration-dependency as 
well as by the production of specific degradation products. Further, to use a 
gastric tumour mouse model and evaluate differences in protease activity on 
tumorous tissue as compared to non-tumourous tissue. 
(3) To demonstrate the transferability of the developed MALDI MSI method to 
relevant clinical samples by analysing the proteolytic activity of human tissue 
biopsies of gastroscopy. 
Part (II) Methods that should be applied in clinical routine require a high degree of 
standardisation, in particular, if a workflow requires multiple steps. On-slide digestion 
of FFPE tissue for MALDI MSI is such a multi-step workflow that consists of dewaxing, 
antigen retrieval, digestion and imaging. Several protocols have been published, but 
little is known about suitable statistical scores for method comparison and 
standardisation. That is why the aims in part II of this study are the following: 
(4) To develop scores suitable for standardisation (unbiased, low computational 
effort) of on-tissue digestion workflow for MALDI MSI by the use of clinical 
material processed with already published methods. 
(5) To detect the best on-tissue digestion method for FFPE tissue and MALDI MSI 
in terms of repeatability and homogeneity of the application system. 
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3 MATERIALS AND METHODS 
3.1 Materials  
Reagents 
NAME 
CATALOGUE 
NB. 
COMPANY LOCATION 
2,5 Dihydroxybenzoic Acid  
(for endogenous digest 
experiments) 
A11459 Alfa Aesar 
Karlsruhe, 
GER 
2,5 Dihydroxybenzoic Acid  
(for FFPE tissue digest) 
8201346  Bruker Daltonics 
Bremen,  
GER 
Acetone 20067.320  VWR 
Darmstadt, 
GER 
Acetonitrile (for MALDI MS 
analysis) 
83640.320  VWR 
Fontenay-
sous-Bains, 
FRA 
Ammonium bicarbonate FL40867 Fluka Analytical 
Munich,  
GER 
Ammonium formate 84884.180E VWR 
Fontenay-
sous-Bains, 
FRA 
Bovine serum albumin  A2153 Sigma Aldrich 
Steinberg, 
GER 
Bradford Reagent B6916 Sigma Aldrich 
Steinberg, 
GER 
Carboxymethyl Cellulose 6190.1 Carl Roth 
Karlsruhe, 
GER 
Casein (from bovine milk) C7078 Sigma Aldrich 
Steinberg, 
GER 
Citric acid monohydrate 211018.1214 AppliChem  
Darmstadt, 
GER 
Cytochrome C (equine heart) C2506 Sigma Aldrich 
Steinberg, 
GER 
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Eosin G solution 0.5% X883.1 Carl Roth 
Karlsruhe, 
GER 
Ethanol absolute 20821.330 VWR 
Fontenay-
sous-Bains, 
FRA 
Folin & Ciocalteau’s phenol 
reagent 
F9252 Sigma Aldrich 
Steinberg, 
GER 
Formic acid 069141 
Biosolve 
Chemicals 
Dieuze,  
FRA 
Hydrochloride acid 9277.2 Carl Roth 
Karlsruhe, 
GER 
L-tyrosine T3754 Carl Roth 
Karlsruhe, 
GER 
Magnesium sulfate 0682.1 Carl Roth 
Karlsruhe, 
GER 
Mayer’s Hematoxylin MHS16 Sigma Aldrich 
Steinberg, 
GER 
Methanol 
8201346  
 
VWR 
Fontenay-
sous-Bains, 
FRA 
Myoglobin 
(from equine skeletal muscle) 
M0630 Sigma Aldrich 
Steinberg, 
GER 
Pancreatin (from porcine 
pancreas) 
P1625 Sigma Aldrich 
Steinberg, 
GER 
Phosphate buffered saline L0615 biowest 
Darmstadt, 
GER 
Potassium 
hydrogenphosphate  
105104 Merck 
Darmstadt, 
GER 
Protease Inhibitor Mix P2714 Sigma Aldrich 
Steinberg, 
GER 
RapiGest SF Surfactant 
3-[(2-methyl-2-undecyl-1,3-
dioxolan-4-yl)methoxy]-1-
propansulfonat 
186001861 Waters 
Milford,  
USA 
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Rhodamine B R6626 Sigma Aldrich 
Steinberg, 
GER 
rLys-C (from E.coli) V1671 Promega 
Madison, WI, 
USA 
rLys-C-Trypsin-Mix V5071 Promega 
Madison, WI, 
USA 
Sodium bicarbonate 8551.1 Carl Roth 
Karlsruhe, 
GER 
Sodium carbonate  S2127 Merck 
Darmstadt, 
GER 
Sodium dodecylsulfate A0676 AppliChem 
Darmstadt, 
GER 
Substance P acetate salt 4010600 BACHEM 
Bubendorf, 
CHE 
T-PER™ 
Tissue Protein Extraction 
Reagent 
78510 
Thermo Fisher 
Scientific 
Rockford,  
USA 
Trichloroacetic acid T0699 Sigma Aldrich 
Steinberg, 
GER 
Trifluoroacetic Acid 8082600025 Merck 
Darmstadt, 
GER 
TRIS buffer A2264 AppliChem 
Darmstadt, 
GER 
Tris(2-
carboxyethyl)phosphine 
646547  Sigma Aldrich 
Steinberg, 
GER 
Triton-X-100 108643 Merck 
Darmstadt, 
GER 
Trypsin gold, mass 
spectrometry grade 
V5280 Promega  
Madison, WI, 
USA 
Xylene 28973.328 VWR 
Fontenay-
sous-Bains, 
FRA 
α-cyano-4-hydroxycinnamic 
acid 
8201344 Bruker Daltonics 
Bremen,  
GER 
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Equipment 
 
NAME COMPANY LOCATION 
Aperio CS2 Leica Biosystems Nußloch, GER 
Cryostat Leica CM 1950 Leica Biosystems Nussloch, GER 
Decloaking Chamber BioCare Medical Concord CA,USA  
Electro Multiscan Spectrum 
Thermo Fisher 
Scientific 
Rockford, USA 
ImagePrep Bruker Daltonics Bremen, GER 
Matrix application device Sun Collect 
with Dispenser Pump  
(for MALDI matrix) 
SunChrom Friedrichsdorf, GER 
Matrix application device Sun Collect 
with Syringe Pump  
(for enzymes and substrates) 
SunChrom Friedrichsdorf, GER 
RapiFlex MALDI TOF/TOF MS Bruker Daltonics Bremen, GER 
solariX MALDI-FT-ICR MS Bruker Daltonics Bremen, GER 
SunDigest device SunChrom Friedrichsdorf, GER 
Ultraflex MALDI-TOF/TOF MS Bruker Daltonics Bremen, GER 
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Consumables 
 
NAME COMPANY LOCATION 
MALDI ITO glass slides Bruker Daltonics Bremen, GER 
Peptide calibration 
standard II  
Bruker Daltonics Bremen, GER 
Protein calibration 
standard I 
Bruker Daltonics Bremen, GER 
Starfrost adhesive slides R. Langenbrinck  Emmendingen, GER 
Water sensitive paper Syngenta Basel, CHE 
 
Software 
 
NAME COMPANY LOCATION 
BioTools Bruker Daltonics Bremen, GER 
Excel Microsoft Redmond, USA 
flexControl Bruker Daltonics Bremen, GER 
flexImaging 4.1 Bruker Daltonics Bremen, GER 
GraphPad Prism GraphPad Software La Jolla, USA 
Image J ImageJ (Wayne Rasband) Maryland, USA 
MATLAB R2017a The Mathworks Natick, USA 
mMass - Open Source 
Mass Spectrometry Tool 
By Martin Strohalm  
R (V 3.2.3.) 
R Foundation of Statistical 
Computing 
Vienna, AUT 
Scils SCiLS GmbH Bremen, GER 
Tableau Tableau Software Inc. Seattle, USA 
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3.2 Tissue samples and ethics approval 
Porcine tissue 
Porcine tissue was collected from the local slaughterhouse, prepared in tissue blocks 
of 2 x 2 cm and immediately frozen to -80 °C.  
TCEA mouse model 
Transgenic CEA424-SV40 Tag C57BL/6 J mice developing spontaneous gastric 
carcinoma110 were grown in our collaborating group of Dr. Elke Burgermeister (Prof. 
Dr. Matthias Ebert, Department of Medicine II, Medical Faculty Mannheim, Heidelberg 
University). Stomachs from TCEA-Tag positive mice and WT mice were collected and 
immediately frozen to -80 °C. All experiments have been ethically approved of 
Heidelberg University and government authorities (Az I-17/07). 
Human gastric biopsies 
Needle biopsies were taken from two patients undergoing gastroscopy (provided by 
Dr. Tobias Gropp (Department of Medicine II, Medical Faculty Mannheim, Heidelberg 
University) and immediately frozen to -80 °C. Studies were conducted in agreement 
with ethical guidelines by the Medical Ethics Committee II of the Medical Faculty 
Mannheim, Heidelberg (2014-633N-MA). 
Human FFPE tissue specimen 
Human liver and gastrointestinal-stromal tumour (GIST) tissue were preserved using 
standard fixation procedure of 10 % neutral buffered formalin for 24±4 h at RT followed 
by paraffin embedding (approval by the Medical Ethics Committee II of the Medical 
Faculty Mannheim, Heidelberg University #2015-868R-MA). Based on H&E stained 
consecutive tissue slices an expert pathologist (Prof. Dr. Alexander Marx, Director of 
the Institute of Pathology, University Medical Centre Mannheim, Heidelberg University 
) has judged the tissue to be >98 % homogeneous (Figure 3).  
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Figure 3: H&E assessment of tissue homogeneity of FFPE preserved tissue H&E staining of the two tissue 
samples GIST (left) and liver (right) was judged 98 % homogeneous by the expert pathologist Prof Dr Alexander 
Marx (Director of Institute of Pathology, University Medical Centre Mannheim). 
 
3.3 Sample Preparation Methods 
3.3.1 Preparation of tissue for monitoring endogenous protease activity 
Scores for evaluating spray quality 
To assess the spray quality substance P (20 pmol/µL in H2O, 3 x 15 µL/min, Speed in 
X= Low 4, Speed in Y= Medium 1) was sprayed on Water Sensitive Paper WSP 
(Syngenta) in two different spray heights: Z-Position = 45.3 mm or 25.5 mm. The 
sprayed paper was scanned using Aperio CS2 (Leica Biosystems). The image was 
converted into grey scale 32-bit using the software ImageJ111 (ImageJ) for quantitative 
analysis. Three equally sized and randomly chosen squares were analyzed for their 
mean grey scale value and the standard deviation in the squares. Values of three 
technical replicates were averaged. 
For further investigation, the spray conditions porcine tissue was cut into 10 µm 
sections and melted on ITO-glass slides. On each tissue 3 x 1µL Rhodamine B 
(1 µg/ml in H2O) were pipetted and dried under vacuum for 5 min. The slides were 
sprayed with substance P using the same two different spraying conditions. 
Rhodamine B spots were visually compared before and after spraying. 
H&E staining 
Sequential sections of frozen porcine tissue were sliced in 2 µm sections and melted 
on Starfrost adhesive glass slides (R. Langenbrinck). Nuclei were stained in Mayer’s 
hematoxylin solution for 2 min. To remove the residual dye, slides were washed in tap 
water (3 min) and then dipped in distilled water. Staining is enhanced with a bath in 
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0.3 % acidic alcohol (0.3 % HCl in 70 % ethanol) for 30 sec, rinsed in distilled water 
and bathed in blueing solution (2 g/L sodium bicarbonate, 20 g/L magnesium sulfate 
in H2O) for 2 min. Eosinophilic structures were stained in eosin solution 0.5 % (5 min) 
and washed in distilled water (1 min). Dehydration was performed in increasing 
ethanol-series (80 %, 96 %, 100 %) for 2 min each. After air-drying the slides, tissue 
was covered with Eukitt mounting medium and dried overnight (ON) before scanning. 
As TCEA mouse stomachs were H&E-stained after MALDI MSI (tissue remains intact, 
as laser shots only in matrix112), additional washing steps were required to remove the 
MALDI matrix. These steps comprise 50 %, 70 % and two times 100 % methanol baths 
(3 min each). Afterwards the tissue was washed in 100 % acetone (5 min) and 
rehydrated firstly in tap water and secondly in distilled water for 5 min each. 
Evaluation of endogenous protease activity on porcine tissue 
Porcine tissue blocks were sliced in 10 µm slices using cryostat CM 1950 (Leica 
Biosystems) with chamber- and head-temperature of -17 °C. Tissue slices were thaw-
mounted on conductive ITO-slides. One slice of all the tissues was directly covered 
with MALDI matrix to assess the specificity of the methods. Further slides were 
desiccated for 5 min at RT and further dried in vacuum at 4°C for 15 min. To monitor 
the proteolytic activity a “digest” and a “no-digest” slide was prepared with sequential 
tissue sections (Figure 4).  
To evaluate the incubation-time-dependency of proteolytic activity with and without 
inhibitor, four spots of 1 µL protease inhibitor mix 1x (PIM) were pipetted on the tissue 
slices. Further, 1 µL solvent of the PIM, namely H2O was pipetted on each tissue to 
assess solvent-related changes. The PIM is a mixture of protease inhibitors purchased 
by Sigma-Aldrich (), consisting of inhibitors listed in Table 3.  
To evaluate inhibitor-concentration-dependency dilution series of the PIM were 
pipetted on the porcine tissue (1 µL of 0x, 0.1x, 0.5x, 0.5x, 1x, 2.5x and 10x PIM) at 
randomly chosen positions (N=2). Slides were kept on ice during the preparation 
procedure. 
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Figure 4: Workflow of tissue preparation for monitoring proteolytic activity using substance P as a 
substrate, One “digest” slide and one “no-digest” slide was prepared to bypass the variability of data introduced 
by measurements on different days and instrument conditions. For porcine experiments protease inhibitor-mix 
was pipetted onto the tissue to assess incubation-time-dependency and inhibitor-concentration-dependency. 
Substance P was sprayed onto the “digest” slide before and on the “no digest” slide after incubation at 37 °C 
and 95% humidity. During sample preparation the slides were kept on ice to prevent uncontrolled digestion. 
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Table 3: Composition of protease inhibitor mix (PIM) in working solution concentration of 1x 
Inhibitor 
Final working 
concentration 
Target proteases 
AEBSF 2 mM Serine proteases 
Aprotinin 0.3 µM Serine proteases 
Bestatine hydrochloride 116 µM Aminopeptidases 
E-64 14 µM Cysteine proteases 
EDTA 1 mM Metalloproteases 
Leupeptin 1 µM Serine- and cysteine proteases 
(AEBSF = 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride; EDTA = ethylenediaminetetraacetic 
acid) 
 
After drying the tissue under vacuum for 3-5 min, the digest slides were sprayed with 
tracer substrate substance P (20 pmol/µL in H2O) with the following spray conditions: 
3 x 15 µL/min, Y-distance 25.5 mm, Speed in X= Low 4, Speed in Y= Medium 1, on 
cool pad. This resulted in a final amount of 3.5 pmol/mm2 substance P. After drying the 
slide briefly under vacuum, incubation was performed with both slides (“digest” and 
“no-digest”-slide) in different periods of time (15 min, 30 min, 45 min, 60 min, 120 min 
and 360 min) to assess time-dependent proteolytic activity. The incubation was one 
time performed in a standard cell culture oven at 37 °C and a second time in SunDigest 
incubation chamber (SunChrom) on a controlled condition of 37 °C and 95% humidityc. 
One incubation-time-dependency dataset consists of 60 single tissue datasets: 5 time-
points x 6 organs x 2 conditions - digest and no-digest.  
For the inhibitor-concentration-dependency and single-inhibitor experiment tissue was 
incubated for 60 min in the SunDigest incubation chamber at 37 °C and 95% humidity. 
Two full technical replicates were performed. 
3.3.2 Adaptation of a tissue protease activity assay (TPAA) 
Optimisation of the extraction process 
The commercially available Tissue Protein Extraction Reagent T-PER (Thermo Fisher 
Scientific) is described to extract total protein amount under a mild condition in their 
active form. Conserved functionality is essential for a protease activity assay. A blank 
                                            
c Experiments in SunDigest incubation chamber had been performed by Kevin Reinle in the context of 
his masterthesis: Visualising endogeneous protease activity by MALDI Mass Spectrometry Imaging, 
2017 
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dilution series of T-PER were performed to evaluate the influencing absorption. 
Further, extraction of 500 mg/mL porcine spleen was performed with T-PER and 
extraction buffer (PBS / 1% (w/v) Triton-X-100 / 0.05% (w/v) SDS) at pH 7.5 and 
pH 3.2.  
Protease activity of porcine tissue 
Frozen porcine tissues were cut into 30 µm slices. Six slices were collected for one 
extraction. Extraction was performed in 500 mg/mL wet tissue. Samples underwent 
five cycles of sonication (5 min) and cooling on ice (2 min). The mixture was 
centrifuged (5 min, 10,000 x g), the supernatant was collected and placed on ice. 
Protein quantification was done by Bradford assay: Tissue extract was diluted 1:100 in 
H2O. In a 96-well plate, 200 µL Bradford-reagent (1x) was mixed with 5 µL samples or 
calibration solution (500, 200, 100, 50, 0 µg/mL BSA in H2O) and incubated for 25 min 
at RT in the dark. Absorption was measured at 595 nm. 
Based on Cupp-Enyards protease activity assay for pure protein solution the tissue 
was tested for its proteolytic activity113. 500 µL casein (0.65% (w/v) in 50 mM K2HPO4) 
was placed at 37 °C (5 min). Then 100 µL protein extract was added and incubated for 
10 min at 37 °C. The reaction was stopped by adding 500 µL 110 mM TCA and 
additional incubation for 30 min at 37 °C was performed. Protein precipitate was 
separated by centrifugation for 5 min at 10.000xg. Finally, 500 µL of 500 mM sodium 
carbonate and 100 µL Folin & Ciocalteau’s phenol reagent was added to the 
supernatant and incubated at 37 °C for 30 min. Native pancreatin solution (1 mg/mL in 
H2O), which is a protease extract from porcine pancreas (Sigma Aldrich), was used as 
positive control. Heat-denatured pancreatin solution (20 min, 95°C) was used as 
negative control. L-tyrosine dilution series (0.0055, 0.011, 0.022, 0.044, 0.055, 0.077 
and 0.11 µmol) were prepared in tissue extraction buffer, which also serves for blank 
measurements. Absorbance was measured in 96-well plates at 660 nm and the activity 
calculation was performed by the following equation (1). Values were further multiplied 
by the quantified protein amount (mg/mL) to gain activity in U/mg. 
𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 [
𝑢𝑛𝑖𝑡
𝑚𝐿
]
=  
𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 𝑡𝑦𝑟𝑜𝑠𝑖𝑛𝑒[µ𝑚𝑜𝑙] 𝑥 𝑎𝑠𝑠𝑎𝑦 𝑣𝑜𝑙𝑢𝑚𝑒[𝑚𝐿]
𝑒𝑛𝑧𝑦𝑚𝑒 𝑣𝑜𝑙𝑢𝑚𝑒 [𝑚𝐿] 𝑥 𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑖𝑜𝑛 𝑡𝑖𝑚𝑒 [𝑚𝑖𝑛] 𝑥 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑚𝑒𝑛𝑡 𝑣𝑜𝑙𝑢𝑚𝑒 [𝑚𝐿]
 
(1) 
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3.3.3 Monitoring protease activity in a gastric tumour mouse model and human 
biopsy                                                                 
TCEA positive, wild-type mouse stomachs and human biopsies (normal gastric tissue 
and adenoma) were sliced in 10 µm tissue slices and melted on conductive ITO glass 
slides. ITO-slices with tissue were kept at RT for different time periods. To assess 
proteolytic activity each tissue was prepared two times, where one is used “without 
inhibitor (-)” and the other “with inhibitor (+)”. Tissues were evacuated at RT for 5 min 
and then dried under vacuum at 4 °C for 15 min. The +inhibitor tissue was covered 
with PIM (1x) using 3 x 15 µL/min, Y-distance 25.5 mm, Speed in X= Low 4, Speed in 
Y= Medium 1, resulting in 0.2 µL/mm2 PIM. After brief drying under vacuum, tracer 
substrate substance P (20 pmol/µL in H2O) was sprayed on both tissues with the same 
spray settings (3.5 pmol/mm2 substance P). All steps were performed on ice. An initial 
experiment for optimising the incubation time for mouse stomach tissue revealed that 
30 min incubation time at 37 °C and 95% humidity in the SunDigest incubation 
chamber is superior to an incubation time of 60 min (Figure 26). After incubation the 
tissue was immediately covered with the MALDI matrix. 
For selectivity evaluation one slice of all tissues was not covered with substance P. It 
was rather incubated and then covered with MALDI matrix. Further, ITO-slides with 
tissue of mouse stomach were kept at RT for different periods (0, 5, 10, 15, 60 min) to 
asses ageing-related changes of the spectra. 
To evaluate the environmental influence of the tissue on the proteolytic activity, 
immediately after slicing TCEA positive stomachs tissues were rinsed with 2 x 1 mL 
50 mM ammonium formate (pH 3 and pH 7). Results were compared with the standard 
proteolytic activity without the washing step (N=3). 
3.3.4 Tissue preparation for quantitative proteomics analysis of mouse tissue 
extracts                                                               
For proteomics analysis three biological replicates of frozen TCEA-positive and WT 
mouse stomachs were cryosectioned into 6 x 60 µm slices and collected in vials (3 
technical replicates for each WT sample, 2 technical replicates for all TCEA-positive 
samples). For direct MALDI MSI one slice (10 µm) of each tissue was thaw-mounted 
onto ITO-slides and vacuum-dried. The aim was to determine the tumour location in 
TCEA-positive mouse stomachs based on the local distribution of PC(34:1)+K+. After 
that, further slices were produced. 
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Figure 5: Preparation of mouse stomachs for quantitative proteomics analysis Frozen tissue (wild-type = 
WT and tumour containing stomach = TS) was cut into 6 x 60 µm slices on a cryostat. For WT 3 technical 
replicates were collected and for TS 2 technical replicates were collected in vials. One slice (10 µm) of each 
tissue was thaw-mounted onto ITO-slides for acquiring MALDI MSI. According to Hinsenkamp et al. PC(34:1)+K+ 
is enriched in the tumour114, its location in TCEA positive stomachs was determined. The tumour-regions (T) 
were manually excised from non-tumour tissue (NT) and collected in vials. Vials containing tissue were stored 
at  -80 °C until further processing. 
 
Tumour-regions and non-tumour regions were excised manually, collected in separate 
vials and stored at -80 °C until further processing (Figure 5).  
Further processing, data acquisition, and data analysis were kindly performed by our 
collaboration partners of the German Cancer Research Center (DKFZ), group of Prof. 
Dr. Jeroen Krijgsveld. The detailed description of procedures and results were 
described in Erich et al115. 
3.3.5 MALDI Matrix application 
All tissues for assessing endogenous proteolytic activity were covered with MALDI 
matrix DHB (60 mg/mL in 50% ACN/ 49.5% H2O/ 0.5% TFA) using the SunCollect 
dispenser system (10, 15, 20, 20, 20 µL/min flow, 300 mm/min speed). 
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3.3.6 Preparation of FFPE tissue for the development of statistical scores 
The tissue blocks were cut in 2 µm slices using standard microtome instrument (at 
Institute of Pathology, University Medical Centre Mannheim). One slice of each tissue 
was placed on indium-tin-oxide (ITO)-slides (Bruker, Bremen) and dried at RT ON. In 
order to reveal the ideal method published in terms of reproducibility and 
homogeneous application, five different methods were tested based on four well-
documented and published methods90,94–96. For easy assessment of similarities and 
differences in the multistep process Figure 6 describes the methods in all details. Each 
method was performed in three technical replicates. The detailed spray settings for all 
five methods were summarised in Table 4. 
Score evaluation for digest efficiency 
To find a suitable standard protein for monitoring the digest efficiency myoglobin 
(100 µM in ddH2O) and cytochrome c (100 µM in ddH2O) were prepared. These two 
proteins have a low molecular weight (16.7 kDa and 12.4 kDa, respectively) and are 
measurable in linear mode using MALDI MSI. An ITO slide with human liver was 
deparaffinised according to method I, II and III (steps are identical). Standard proteins 
were pipetted three times with 1 µL on one tissue and on the ITO slide before 
incubation (“digest”). The whole slide was sprayed with trypsin (0.1 µg/µL in 90% 
100 mM ABC buffer/10% ACN) according to method I. After the incubation time of 2 h 
at 37 °C with 95 % humidity in SunDigest device (SunChrom, Friedrichsdorf), 1 µL 
standard protein solutions were pipetted three times on the second tissue and on the 
ITO slide. Prior to data acquisition the slide was covered with MALDI matrix DHB with 
method I. 
1 µL of standard protein cytochrome C (1 mg/mL in ddH2O) was pipetted on the slide 
next to the tissue before and after the incubation to monitor the protease activity in the 
method-comparison-experiments. 
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Method II
Casadonte et. 
al. (2015)
Method V
Diehl et. al. 
(2015) using 
DHB
Method III
Casadonte et. 
al. (2011) with 
Heijs et. al. 
(2015)
Method I
Casadonte et. 
al. (2011) with 
SunCollect 
Sprayer
2x3min Xylol
EtOH 100-100-96-
70% (1min each)
2x3min H2O
All start with FFPE tissue 2 µm
In 10mM Tris 
buffer, 
pH 9.0
Decloaking 
chamber with 
500mL water
95°C – 20min
90°C – 10min
Cool down at RT
Exchange buffer 
to H20; 
Dry on filter paper
Image Prep: 
100ng/µL Trypsin 
in 40mM ABC-
buffer/10%ACN; 
1.5h, 37°C
Image Prep: 
HCCA 7mg/mL (in 
50%ACN/
0.5%TFA)
50µm, UltrafleXtreme
melt 1h. 60°C
2x5min Xylol
2x2min EtOH
2x3min 10mM 
ABC-buffer
Microwave:
10mM citric acid 
pH6 (pulse boil for 
10min,  water 
bath- 30min, 98°C)
Cool down 5 min
2x1min 10mM 
ABC-buffer
5 min desiccator
Image Prep: 
100ng/µL Trypsin 
in 50mM ABC-
buffer, 2h, 37°C
Image Prep: 
DHB 30mg/mL in 
50%MeOH/1%TFA
2x3min Xylol
EtOH 100-100-96-
70% (1min each)
2x3min H2O
In 10mM Tris 
buffer, 
pH 9.0
Decloaking 
chamber with 
500mL water
95°C – 20min
90°C – 10min
Cool down at RT
Exchange buffer 
to H20; 
Dry on filter paper
SunCollect: 20ng/
µL Trypsin in 
ddH2O
37°C, 18h in 50% 
MeOH in 
saturated 
chamber
SunCollect: 25mg/
mL DHB in 50% 
ACN/0.1%TFA
2x3min Xylol
EtOH 100-100-96-
70% (1min each)
2x3min H2O
In 10mM Tris 
buffer, 
pH 9.0
Decloaking 
chamber with 
500mL water
95°C – 20min
90°C – 10min
Cool down at RT
Exchange buffer 
to H20; 
Dry in exciccator
SunCollect: 
100ng/µL Trypsin 
in 40mM ABC-
buffer/10%ACN; 
2h, 50°C
5x15µL/min 
(Low10, HIgh5)
SunCollect: 60mg/
mL DHB in 
50%ACN/0.2%TFA
10-15-20-20-20µL/
min
300mm/min
Method IV
Diehl et. al. 
(2015) using 
HCCA
melt 1h. 60°C
2x5min Xylol
2x2min EtOH
2x3min 10mM 
ABC-buffer
Microwave:
10mM citric acid 
pH6 (pulse boil for 
10min,  water 
bath- 30min, 98°C)
Cool down 5 min
2x1min 10mM 
ABC-buffer
5 min desiccator
Image Prep: 
100ng/µL Trypsin 
in 50mM ABC-
buffer, 2h, 37°C
Image Prep: 
HCCA 5mg/mL (in 
50%ACN/2%TFA)
Aquisition
Antigen-
Retrieval
Digest
Matrix
Dewaxing
Re-
hydration
Buffer 
exchange
 
Figure 6: Overview of methods for FFPE tissue digestion Method I and Method II are based on Casadonte 
and Caprioli90, and R. Casadonte et al.94, respectively. Method III is a combination of Dewaxing, Rehydration, 
Antigen-Retrieval and Buffer exchange of Method I / II with spraying conditions for digestion and matrix published 
by Heijs et al.95. Method IV and V are both published by Diehl et al.96 and differ only in the chosen matrix and its 
application conditions. 
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Table 4: Detailed setting for enzyme and matrix application of each method The SunCollect system requires 
several settings to spray a defined amount of solvent. Those settings include X and Y vial distances and speed in 
X and Y direction. For matrix and enzyme application using the ImagePrep, the settings are saved in the named 
method files supplied by the supplier (Bruker Daltonics). 
Method Enzyme application settings Matrix application settings 
I 
SunCollect 
Vial X = 0.5 mm 
Vial Y = 2 mm 
Z-Offset = 1 mm 
5 layers, each 15 µL/min 
Z-Position = 45.28 mm 
Speed in X = Low 10 
Speed in Y = High 5 
SunCollect 
Vial Y = 2 mm 
5 layers, 10, 15, 20, 20, 20 µL/min 
Z-Position = 28 mm 
300 mm/min 
II 
ImagePrep 
TrypsinDeposition_nsh03.par 
ImagePrep 
HCCA_nsh04.par 
III 
SunCollect 
Vial X = 0.3 mm 
Vial Y = 0.3 mm 
Z-Offset = 0 mm 
5 layers, each 5 µL/min 
Z-Position = 45.28 mm 
Speed in X = Low 4 
Speed in Y = Medium 1 
SunCollect 
Vial X = 0.5 mm 
Vial Y = 2.0 mm 
Z-Offset = 0 mm 
3 layers, 10, 35, 35 µL/min 
Z-Position = 25.00 mm 
Speed in X = Low 3 
Speed in Y = Medium 1 
IV 
ImagePrep 
TrypsinDeposition_nsh03.par 
ImagePrep 
HCCA_nsh04.par + one additional 
cycle 
V 
ImagePrep 
TrypsinDeposition_nsh03.par 
ImagePrep 
DHB_nsh04.par + one additional cycle 
 
3.4 MALDI MS imaging data acquisition methods 
Assessment of endogenous protease activity in porcine tissues 
Porcine tissues were analysed using an UltrafleXtreme MALDI-TOF/TOF MS 
instrument in reflector positive mode and a mass range of 500-2500 Da. The lateral 
resolution was 200 µm, summing up 300 shots per pixel. External quadratic mass 
calibration was performed by using peptide standard II.  
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Assessment of endogenous protease activity in a gastric tumour mouse model 
and human biopsy 
Mouse-derived samples and human biopsies were measured using a RapifleX MALDI-
TOF MS instrument (Bruker Daltonics) with a lateral resolution of 50 µm (and 20 µm 
for the high-spatial resolution replicate experiment on mouse stomach), summing up 
400 shots per pixel. The same slides were further analysed using 7T solariX XR MALDI 
FT-ICR MS instrument (Bruker Daltonics) in a mass range of 100 – 3000 Da and a 
raster width of 20 µm with 15 laser shots/pixel. Additional parameters were summed in 
Table 5. Spectra were recorded using 512 k (FID 0.2447 s) data point transient, 
corresponding to an estimated resolving power of 33,000 at m/z 400. With these 
settings the data size has a manageable size of 22 GB. Internal calibration was 
performed using a lock mass of m/z 780.551 [PC(34:2)+Na+]. For verification of the 
substance P fragments on mouse stomachs, CID fragmentation was used with 
individually optimised voltages. Data analysis was done using Biotools 3.2 and 
Sequence Editor 3.2 software. 
 
Table 5: Parameters for FT-ICR MSI of mouse stomach tissue and human biopsy 
Ion transfer 
Funnel 1  150 V 
Skimmer 1 15 V 
Funnel RF Amplitude 70 Vpp 
Octapole 
Frequency 5 MHz 
RF Amplitude 350 Vpp 
Collision cell 
RF Frequency 2 MHz 
RF Amplitude 1200 Vpp 
Transfer optics 
Time of Flight 1.5 ms 
Frequency 4 MHz 
FR Amplitude 350 Vpp 
Quadrupole Q1 Mass 350 m/z 
Excitation mode 
Sweep excitation ON 
Sweep step time 15 µs 
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Acquisition of FFPE on-tissue digestion experiments 
Data acquisition was performed on an UltrafleXtreme MALDI TOF/TOF instrument 
(Bruker Daltonics) in reflector positive (RP) mode and in a mass range of 500-5000 
Da. On each tissue slice, three squares (~ 110 pixels each) were randomly selected in 
the trypsin-coated part and in the “no-trypsin control”. Those six squares per tissue 
slice were measured with 50 µm pixel-to-pixel resolution, medium laser size, and 500 
shots per pixel. Standard protein spots were measured in the linear positive (LP) mode 
in a mass range of 2000-20,000 Da using a raster width of 200 µm and a large laser 
focus. Peptide method calibration was performed using external peptide calibration 
standard II for reflector positive mode. Protein linear method calibration was performed 
using protein calibration standard I and external quadratic calibration. All acquired 
datasets were converted into SCiLS Lab – files performing a baseline subtraction 
during the import (TopHat, width 200). Additionally, all datasets were exported into 
imzML format116 for in-house computational analysis.  
3.5 Data processing and statistical methods 
3.5.1 Statistical analysis for digests by endogenous proteases in mouse 
stomach  
TOF datasets were converted into imzML format116 using the flexImaging converter. 
FT-ICR data were converted to imzML by an in-house conversion tool. Statistical 
analysis has been done by Denis Abu-Sammour explained in details in Erich et al.115 
FT-ICR datasets were uploaded to METASPACEd 117 and are publicly available. 
Proteomics data processing 
Proteomics data were processed by Torsten Müller of the German Cancer Research 
Center (DKFZ), group of Prof. Dr. Jeroen Kriijgsveld, as described in Erich et al.115. 
Data is publicly available in ProteomeXchange Consortium via PRIDE repository 
(identifier PXD010369). 
                                            
d http://metaspace2020.eu 
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3.5.2 Data processing for FFPE-tissue trypsin digests score development 
Evaluation of the sequence coverage 
To evaluate the sequence coverage of the myoglobin and cytochrome C digest spectra 
from reflector-positive measurements were analysed and compared to in situ digest 
using BioTools software and sequence editor applying a mass tolerance of 100 ppm. 
Further, the values for a number of matched peptides are extracted. 
Calculation of Digest Efficiency DE% 
For FFPE-tissue experiments the total ion current- (TIC-) normalised intensities of each 
intact signal of cytochrome C [M+H]+, [M+H]2+ and [M+H]3+ were exported for the 
undigested and digested spot by SCiLS Lab. Digest efficiency was calculated for each 
signal using the following formula and was further averaged resulting in the DE% for 
the respective slide.  
𝐷𝐸% = ( 1 −
𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦𝑑𝑖𝑔𝑒𝑠𝑡𝑒𝑑
𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦𝑢𝑛𝑑𝑖𝑔𝑒𝑠𝑡𝑒𝑑
) × 100% (2) 
 
For quantifying protease activity regions-of-interest (ROIs) were manually drawn on 
the tissue spots with inhibitor (+inhibitor) and randomly on tissue without (-inhibitor) 
inhibitor in flexImaging. Mean spectra were exported into mMass, where baseline-
subtraction and peak-picking (S/N>5) were performed. Intensities for substance P 
signal in each ROI were exported into Excel. DE% was calculated as described in 
equation (2). (Graphical visualisation and regression analysis have been done in Prism 
5.0). 
Data processing for FFPE on-tissue trypsin digests 
The here briefly explained computational analysis of FFPE tissue digest was 
performed by my colleague Denis Abu-Sammour. Raw data were imported as imzML 
files into R.3.2.3118, where preprocessing and peak picking were performed. Further 
details are explained in the respective publication by Erich et al.119 The resulting peak 
lists were used for pixel-wise and mean-spectra analysis.  
To visualise the number of picked peaks in defined mass ranges, peaks were grouped 
in Excel and tables were visualised using Tableau – software or GraphPad. The shown 
mean spectra were TIC normed and visualised using mMass software. 
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Correlation and fold-change analysis 
For the analysis of repeatability the peak lists of all replicates were combined to one 
merged peak list. This list contained all occurring m/z values and was generated with 
an in-house script in MATLAB (tolerance 100 ppm). These defined peaks consisted 
most likely of a mixture of underlying molecules102. This is due to the theoretical mass 
accuracy of 0.1 – 0 01 Da for TOF-instruments in the used mass range. As method 
variability was evaluated, the same experimental setup was repeated, and the 
composition of each peak should be consistent throughout the analysis. The coefficient 
of determination R2 was calculated for all peaks and their respective intensities. The 
natural fold-change (natFC) was defined as the absolute value of either 5th or 95th 
percentile of all fold-changes comparison, whatever was higher (equation (3)).  
 
𝑛𝑎𝑡𝐹𝐶 = max (│5𝑡ℎ 𝐹𝐶 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑖𝑙𝑒│, │95𝑡ℎ 𝐹𝐶 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑖𝑙𝑒│) (3) 
 
This score-based analysis has not only been performed on mean spectra as described 
here but also on pixel-wise analysis using computational power (in R) by my colleague 
Denis Abu-Sammour as described in Erich et al.120. For homogeneity analysis 1000 
different, randomly chosen, combinations of spectra were compared for R2 and fold-
change values. To assess repeatability, 3000 different and randomly chosen spectra 
were compared. 
Fold-change calculations on endogenous digest experiments were performed on mean 
spectra and intensities extracted from SCiLS Lab software. Respective datasets were 
converted in SCiLS Lab, common peak-lists were calculated, and respective intensities 
were exported into Excel. Further calculations were performed in Excel and Tableau.  
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4 RESULTS 
4.1 Part I – Visualisation of tissue protease activity using MALDI MSI 
4.1.1 Development of a score for ideal application of the substrate 
The homogeneous application of a substrate is essential for spatial evaluation by 
MALDI MSI. Furthermore, the delocalisation of molecules in the tissue needs to be 
minimised. The next Figure 7 shows an innovative way to measure those factors. 
Applying water on the yellow Water- sensitive paper WSP (Syngenta) turns it blue. It 
is used in agriculture to check spray distribution, droplet density and droplet sizing of 
spray applications on fields121. It allows the visual inspection of spot density (spot/cm2) 
and the automated analysis for spot size parameter, the number of spots and area 
coverage percentage122. So far, it has not been used in MALDI MSI or related spatially 
resolved methods. Spraying an aqueous solution with a sprayer system as the 
SunCollect (SunChrom) on the WSP revealed the droplet distribution (Figure 7 A). 
Using a bigger distance from the spray head to the WSP (25.3 mm) showed a deeper 
blue compared to the sparkled layer with a distance of 45.3 mm. The distance in 
millimetre represented the ascended spray head, thus a higher value meant a lower 
distance to the WSP. Although the visual inspection of the blue layer already indicated 
the advantage of the higher spray distance, an unbiased quantitative analysis is more 
valuable. Therefore, the WSP was scanned, the image converted into grey-scale and 
mean grey values were exported for three randomly chosen squares (ImageJ-
software, Maryland) N=3. The mean grey values for three individual spray experiments 
were plotted in bar charts (Figure 7 B) showing that the higher distance ensured more 
stable and reproducible values.  
The next important prerequisite for an ideal spray condition is a minimal delocalization 
of molecules in the tissue. A Rhodamine B – test was developed to check for 
delocalization. Here, three spots of 1 mg/mL Rhodamine B in water were pipetted on 
the tissue and dried prior to the spray application. With a distance of 45.3 mm the spots 
were spread and the dye was spread over the tissue, whereas with a distance of 
25.3 mm the integrity of the spots was preserved (Figure 7 C). The endogenous digest 
experiments were performed with the optimized setting of 25.3 mm spray distance for 
three layers of 15 µL/mm flow. 
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Figure 7: Spray distance optimization using water sensitive paper (WSP) and the Rhodamin B test Both 
tests were developed for testing spray homogeneity and delocalization, respectively. The yellow water sensitive 
paper (WSP) turns blue when getting into contact with water. A By spraying the solvent on WSP the difference 
in droplet composition was visually inspected. Lower distance to the WSP (45.3 mm) revealed more sparkled 
spray distribution. A higher distance (25.3mm) produced a denser and homogeneous blue colour. B Mean grey 
values were extracted from the blue colour using ImageJ (ImageJ, Maryland) for three randomly chosen squares 
(summed in one bar) and three technical replicates. C For testing delocalization rhodamine B was spotted on 
the tissue, then dried and the tissue was sprayed with solvent. The integrity of the rhodamine B spots was 
observed visually. (N=3) 
4.1.2 Evaluation of substance P as a universal substrate 
In this study substance P has been chosen as substrate. This assumption was 
evaluated by a database search based on ‘MEROPS – the peptidase database’e, which 
confirmed that several protease classes can cleave substance P (Figure 8)25. 
Proteases from organisms like fish, plant, or fungi could cleave substance P. When 
looking into the mammalian species, most MEROPS entries are from Homo sapiens 
(Figure 8 A). For mammals the found proteases belonged to different protease classes, 
                                            
e http://merops.sanger.ac.uk 
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namely peptidylpeptidases, cysteine endopeptidases, aspartic endo-peptidases, 
dipeptidyl peptidases, serine endopeptidases, and metallo-endopeptidases, of which 
the latter two were listed most often (Figure 8 B). A detailed analysis of the recorded 
produced peptides (Figure 11) revealed that SubP(1-7), SubP(1-6) and SubP(1-9), 
referring to m/z 900.5, 753.4 and 104.6, respectively, might be produced predominantly 
by metalloendopeptidases, (Figure 8 C). Indeed, there might be proteases that do not 
cleave substance P. Based on this analysis, however, it seemed far away from being 
a specific substrate, and its use as overall tissue protease activity tracer is reasonable. 
 
 
Figure 8: MEROPS database analysis for substrate substance P A When analysing MEROPS database for 
proteases that could use substance P as a substrate, 44 proteases were found and can be grouped for different 
characteristics like their origin. B Interesting for us are the 23 mammalian proteases grouped for their protease 
class. Most of these are metalloendopeptidases (11 proteases, shown in yellow) C Shown here is the number of 
proteases and their classes sorted by their substance P product specificity. The sorting was based on the 
described substance P – fragments and the related proteolytic class. The most proteases slice substance P at 
position 7 (phenylalanine) to the fragment SubP(1-7). This fragment has the m/z value 900.5. The next most 
abundant fragment SubP(1-6) corresponds to the observed m/z value 753.4 and finally SubP(1-9) has an m/z 
value of 1104.6. According to our data and this analysis, we observe the three most abundantly produced 
substance P fragments. Further, they may be produced mainly by metalloproteases (green colour). 
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4.1.3 Time-course of substance P digestion by endogenous tissue proteases 
For a systematic analysis of tissue protease activity using MALDI MSI the 
undecapeptide substance P (RPKPQQFFGLM; [M+H]+ = m/z 1347.7354) was selected 
as tracer substrate. Porcine tissues (brain, kidney, liver, pancreas, spleen and muscle) 
were tested with if for unspecific whole-tissue protease activity.  
Homogeneity assessment of porcine tissue  
H&E stains or representative tissue slices reveal the inhomogeneity of brain tissue 
(Figure 9). Inhomogeneity can be problematic for the spatial analysis of the 
experimental setup. The homogeneity of all other tissues is a prerequisite for the 
topically applied inhibitor spots in the following experimental setup. 
 
 
Figure 9: H&E stain for porcine tissue All porcine tissue were H&E stained according to standard staining 
protocol. The slides were scanned with high resolution using the Aperio CS2 (Leica Biosystems) scanner. 
Morphology of the tissue showed inhomogeneity for brain tissue, represented by white and grey matter. The 
other tissue blocks showed good homogeneity. 
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Specificity analysis for the tracer peptide and related ions on porcine tissue 
It is another prerequisite that specificity of substance P signals is given for all tissues. 
All porcine tissues were measured using MALDI-TOF MS instrument (UltrafleXtreme, 
Bruker Daltonics) without any application of substance P. The tissue mean spectra did 
not show any signal that potentially could interfere with substance P or substance P–
related signals (Figure 10).  
 
 
Figure 10: Specificity of m/z values of substance P and its related peptides on porcine tissue Shown are 
MALDI-TOF mean mass spectra of porcine tissues (brain=red, kidney=blue, liver=green, muscle=yellow, 
pancreas=grey, spleen=black) without trypsin-coating. No endogenous signals interfere with substance P signal 
at m/z 1347.7 (D) nor with potential resulting peptides at m/z 1104.6 (C), m/z 900.5 (B) or m/z 753.4 (A). 
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MALDI MSI time course visualising tissue protease activity of porcine tissues 
By spray coating, porcine liver tissue with substance P and further incubation at 37 °C 
and with 95% humidity (in SunDigest Incubation chamber) for 30 min a consistent 
decrease of the substance P signal and an increase in substance P-related peptide 
signals were observed (Figure 11), compared to a control without incubation. The 
experiment was designed by myself and conducted by Kevin Reinle in the context of 
his masterthesisf. The detected increasing masses could be assigned to the C-terminal 
cleavage products of substance P (Table 6). This first result led to the hypothesis, that 
the digestion of the tracer substance P by endogenous proteases, preserved in frozen 
tissue, could be visualised. 
 
Table 6: Substance P related peptides C-terminally cleaved 
Substance P 1347.7 m/z RPKPQ QFFGL M 
SubP(1-10) 1217.7 m/z RPKPQ QFFGL 
SubP(1-9) 1104.6 m/z RPKPQ QFFG 
SubP(1-8) 1047.6 m/z RPKPQ QFF 
SubP(1-7) 900.5 m/z RPKPQ QF 
SubP(1-6) 753.4 m/z RPKPQ Q 
SubP(1-5) 625.4 m/z RPKPQ 
 
 
To verify this hypothesis, an experimental setup for all six porcine tissues was 
developed, where time-dependency of the digestion could be observed with MALDI 
MSI. Further, a protease inhibitor mix (PIM) was pipetted (4 x 1 µL in 1x working 
solution, concentrations of single inhibitors according to Table 3) on the tissue, to 
indicate a protease-related change of signal intensity (Figure 4). Incubation was 
performed in the SunDigest incubation chamber.  
                                            
f Masterthesis Kevin Reinle, Visualising endogeneous protease activity by MALDI Mass Spectrometry 
Imaging, 2017 
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Figure 11: Comparison spectra digest/no digest show increased fragments of substance P In an initial 
experiment substance P was sprayed on pancreas tissue – one prior to incubation at 37 °C and 95% humidity, 
for 30 min (digest), the other after this incubation (no digest). The fold-change plot revealed that the digested 
tissue showed decreased substance P signals (in red) compared to no-digest tissue. The set of substance P 
signals consist of the protonated form, adducts with sodium and potassium, as well as their respective 
isotopologues. Further, m/z values increased in the digested tissue (green) that might correspond to cleaved 
products of substance P. 
 
The first observation was that on muscle tissue there was no difference between 
substance P signal distribution on no digest- and digest-slide. This means that no 
reduction of the substance P – signal, thus no digestion could be observed (Figure 12). 
Further, the spotted PIM did not have an impact on the substance P signal distribution 
in both conditions.  
There was a difference in the absolute intensity scale when measuring the time points 
on different days. To normalise this variability, the no digest control was always 
measured with the digest slide. This makes a comparison of the different time-points 
possible. Nevertheless, when the no digest control visually did not show a 
homogeneous distribution of the substance P signal, the data set was excluded for 
further analysis. 
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Figure 12: MALDI MSI of substance P and resulting peptides on porcine muscle Muscle tissue cryosections 
of 10 µm were mounted on two ITO-slides. Protease inhibitor mix was pipetted onto each tissue (4x 1 µL). The 
“digest” and “no-digest” slides were spray-coated with substance P before and after incubation (15, 30, 60, 120, 
360 min), respectively. After coating with DHB, MALDI-TOF MSI was performed at 200 µm spatial resolution. 
For muscle tissue the ion intensity distribution of substance P (m/z 1347.7) on the “digest” slide did not change 
over time. Scale bar is 2 mm. 
 
 
Figure 13: MALDI MSI of substance P and resulting peptides on spleen Tissue was sliced in 10 µm sections 
and placed on two ITO-slides (“digest”-slide and “no-digest”-slide). Protease-Inhibitor-Mix was pipetted onto each 
tissue (4x 1 µL). The “digest”-slide was spray-coated with substance P before and the “no-digest”-slide after 
incubation at 37 °C, 95 % humidity (incubation times: 15, 30, 60, 120, 360 minutes). After coating with MALDI 
matrix, the acquisition was performed on a MALDI-TOF MS (UltrafleXtreme, Bruker Daltonics) with 200 µm 
spatial resolution. MALDI-TOF MS images of the “no-digest”-slide showed a homogeneous distribution of 
substance P. This description holds true for the following figures. On the “digest” slide, the spots with inhibitor 
showed higher substance P signals than the surrounding tissue without inhibitor. Where low substance P signal 
intensity was detected, peptides corresponding to m/z values 1104.6, 900.5 and 753.4 are visible. In the case of 
m/z 900.5 the inhibition retained the decrease of the signal at 120 min incubation. Scale bar is 2 mm. 
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The porcine tissues spleen, liver, pancreas and kidney (Figure 13 to Figure 16) showed 
a time-dependent reduction and a homogeneous distribution of the substance P signal 
on the no digest controls. The spots, where PIM was pipetted, were clearly visible and 
displayed a higher substance P signal compared to the non-inhibited surrounding 
tissue. In detail, when looking at the MALDI MSI of substance P signal distribution on 
spleen after 15 min incubation, very low signal intensity (represented in blue colour) 
could be seen in the non-inhibited regions. In contrast in the PIM spots the intensity 
was preserved. After 120 min of incubation the substance P signal was decreased in 
the PIM spots also, until it was gone after 360 min incubation. The absolute depletion 
of substance P signal holds true for all tissue, apart from muscle.  
 
 
Figure 14: MALDI MSI of substance P and resulting peptides on liver See description of Figure 13. On the 
“digest” slide, the spots with inhibitor showed higher substance P signals than the surrounding tissue without 
inhibitor. Where low substance P signal intensity was detected, peptides corresponding to m/z values 1104.6, 
900.5 and 753.4 are visible. In case of m/z 900.5 the inhibition retained the decrease of the signal at 120 min 
incubation. Scale bar is 2 mm. 
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Figure 15: MALDI MSI of substance P and resulting peptides on pancreas See description of Figure 13. On 
the “digest” slide spots with inhibitor showed higher substance P signals than the surrounding tissue without 
inhibitor. Where low substance P signal intensity was detected, peptides corresponding to m/z values 1104.6, 
900.5 and 753.4 are visible. Pancreas seemingly shows a poor reaction on the spotted inhibitor. Scale bar is 
2 mm. 
 
 
Figure 16: MALDI MSI of substance P and resulting peptides on kidney See description of Figure 13. On 
the “digest” slide spots with inhibitor showed higher substance P signals than the surrounding tissue without 
inhibitor. Where low substance P signal intensity was detected the m/z values 1104.6, 900.5 and 753.4 are 
visible. The inhibition retains the decrease of the signal m/z 900.5 at 120 min incubation. Scale bar is 2 mm 
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As previously mentioned homogeneous distribution of substance P on the no-digest 
control is the prerequisite for a proper statistical analysis. According to the H&E stain 
of brain tissue (Figure 9), the brain sample consists of white and grey matter. This 
inhomogeneity resulted in inhomogeneous distribution of the signal, most likely due to 
different ionisation and suppression effects in the two tissue types123. This generated 
very unreliable and unstable results for this dataset.  
 
 
Figure 17: MALDI MSI of substance P and resulting peptides on brain See description of Figure 13. MALDI 
MSI of the “no-digest”-slide showed inhomogeneous distribution of substance P, due to morphological 
differences in brain tissue. 
 
The MALDI MSI of the time-curve experiment did not only reveal the protease-
dependent decrease of substance P signal (as PIM retains the decrease), but also the 
time-dependent occurrence of substance P-related peptides. The most intense were 
SubP(1-5) m/z 753.4, SubP(1-7) m/z 900.5 and SubP(1-9) m/z 1104.6. With m/z 
1104.6 and 753.4 being dominantly produced in the non-inhibited tissue, m/z 900.5 is 
produced in the PIM spots. This could be optimally observed on spleen (Figure 13). 
Here, after 360 min incubation no difference between inhibited and non-inhibited 
regions was detectable anymore. The time-dependent production of peptides suggests 
that substance P is truly digested rather than sequestered into the tissue. 
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Digest efficiency calculation in the time course experiments 
An absolute analysis of the MALDI MS Images is difficult. All time-points and tissue 
relative digest efficiencies (DE%) were calculated according to equation (2). Mean 
spectra were extracted from the four PIM spots (+ inhibitor) and from tissue without 
PIM (- inhibitor). The substance P intensity for no digest and digest slide were also 
extracted. The time-curve experiments were performed a second time under slightly 
varied conditions: The incubation was done in a standard cell-culture oven at 37 °C 
(Figure 18) instead of the SunDigest incubation chamberg (Figure 19) 
 
 
Figure 18: Time-curves of digest efficiency of porcine tissues in a cell culture incubator All tissue showed 
a very fast increase of DE% when no inhibitor was used (continuous line). The Protease Inhibitor Mix (PIM) 
slowed down the digestion process (broken line). Pancreas did not react on the PIM and showed a very fast 
digestion process. Muscle tissue showed no decrease in substance p signal and was thus used as negative 
control. 
                                            
g Experiments in SunDigest chamber were designed by myself and conducted by Kevin Reinle in the 
framework of his Masterthesis: Visualising endogeneous protease activity by MALDI Mass Spectrometry 
Imaging, 2017 
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Figure 19: Time-courses of digest efficiency of porcine tissues in the incubation chamber All tissue 
showed a very fast increase of DE% when no inhibitor was used (continuous line). The Protease Inhibitor Mix 
(PIM) retarded the digestion process (broken line). Pancreas did not react on the PIM and showed a very fast 
digestion process. Muscle tissue showed no decrease in substance p signal and was thus used as negative 
control. 
 
The calculated DE% in the cell culture incubator showed already 100% digestion of 
the substance P signal after 15 min incubation, lasting on this level in all tissues 
(instead of muscle) (Figure 18). In the SunDigest chamber a nearly 100% digestion for 
all tissues (instead of muscle) was reached after 60 min incubation time (Figure 19). It 
seemed that the conditions in the SunDigest chamber favoured a slow progress of the 
proteolytic activity. Both experiments showed decreased DE% when PIM was applied 
to the tissue. Further, brain showed a high standard deviation according to its tissue 
heterogeneity (data not shown). Porcine pancreas showed no effect on PIM and high 
variance (< 1 h), regardless of the incubation condition. This was possibly due to the 
complexity of protease constitution in this highly active digestive tissue124. In spleen 
and liver tissue PIM-induced retardation of substance P degradation was highly 
significant. Muscle tissue showed no reduction of the substance P signal in both 
conditions, so the calculation of DE% did not show an increase. 
Generation of substance P cleavage products in time course experiment 
It was observed that substance P related peptides occurred transiently during the time 
course. Ion intensities for m/z 1104.6, m/z 900.5 and m/z 753.4 were extracted in 
analogy to the ion intensity extraction of substance P. The TIC-normalised intensities 
from ROIs with and without inhibitor were plotted. In line with the observation from 
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MALDI MSI (Figure 12 to Figure 17) the m/z value 900.5 was predominantly produced 
in inhibited regions (blue line, Figure 20). The other two fragments were produced 
predominantly without inhibitor. This finding suggested that different sets of proteases 
are responsible: 
1. Without PIM: m/z 1347.7  1104.6  753.4  X 
2. With PIM: m/z 1347.7  900.5  X 
In brain, the standard deviations were very high, so no difference could be observed.  
 
 
Figure 20: Transient presence of substance P cleavage products is modulated with PIM TIC-normalised ion 
intensities were extracted from mean spectra of porcine tissue of the areas without (orange line) and with (blue line) 
protease inhibitor mix (PIM) (S/N>5). The intensities of putative substance P cleavage products m/z 1104.6, 900.5 
and 753.4 that are generated transiently are plotted versus the incubation time. Note that m/z 900.5 was recorded 
with higher intensity in PIM containing regions.  
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The effect of PIM indicated that the reduction of substance P signal was not due to 
uncontrolled effects like sequestering or adsorption of substance P into the tissue, but 
rather was related to real protease-driven digestion. 
4.1.4 Inhibitor-concentration dependency of proteolytic activity in porcine 
tissue 
An inhibitor-concentration-dependency of substance P cleavage would be a further 
confirmation of true protease reaction. Different working concentrations of PIM stock 
(10 x, 2.5 x, 1.0 x, 0.5 x, 0.25 x and 0.1 x) were pipetted onto porcine tissue. Tissue 
protease activity was measured using MALDI MSI after 60 min incubation in SunDigest 
incubation chamber (N=2). Mean ion intensities per PIM region were extracted for 
substance P, and DE% was calculated according to equation (2) (Figure 22). Non-
inhibited tissue showed very high DE% values, and muscle displayed essentially no 
protease activity, in line with the time-course results (Figure 19). In analogy with 
previous results and possibly due to heterogeneity brain tissue showed high variance 
(Figure 9). All other tissues showed non-linear decrease of DE% with increasing PIM 
concentration. The final DE% (highest PIM concentrations) are listed in Table 7 in 
ascending order. The tissue with the highest survival potency is pancreas, followed by 
spleen, kidney and liver.  
 
Table 7: DE% values with the highest PIM concentration and survival potency 
tissue DE% (N=2) 
survival 
potency 
muscle No activity  
liver 0 2 
kidney 2 7 
spleen 37 30 
pancreas 57 59 
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Figure 21: Increasing dilutions of PIM promote a concentration-dependent decrease in DE% Protease 
inhibitor mix (PIM) was diluted and pipetted onto each tissue (10 x, 2.5 x, 1.0 x, 0.5 x, 0.25 x, 0.1 x). “Digest” 
slide and “no-digest” slide were prepared and incubated for 60 min (N=2). The calculated DE% was plotted for 
inhibited (filled circles) and non-inhibited (empty circles) regions. Non-linear curve fitting with variable slope and 
four parameters were used. 
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Figure 22: Concentration-dependent attenuation of substance P cleavage by protease inhibitor mix 
dilution series  Protease-Inhibitor-Mix was diluted and pipetted on porcine tissue (A – E) according to the dilution 
scheme in the figure. “Digest”- and “no-digest”-slides were prepared, followed by incubation for 60 min at 37 °C 
and 95% humidity. The experiment was performed two times and both replicates were shown. MALDI-TOF MS 
ion images of substance P (m/z 1347.7 (green)) and a related peptide m/z 900.5 (purple) distribution was shown. 
The no-digest slides showed homogeneous distribution. A solvent spot (H2O) showed no effect on the ionization. 
PIM on muscle (E) showed again no effect, which was consistent with the previous results. 
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4.1.5 Development of a photometric tissue-protease activity assay (TPPA) 
It is one scientific aim to verify gained results with a comparable method. As no method 
for visualising overall protease activity was known, an in-solution method based on C. 
Cupp-Enyard’s ‘universal protease activity assay: casein as substrate’ was adapted113. 
 
In the first run, the extraction of global proteases from tissue was necessary. For that 
a Tissue Protease Extraction Reagent T-PER (Thermo Scientific) was used. The 
reagent was described as a reagent for total protein extraction from tissue. It is mild as 
it contains a minimal amount of detergent for cell lysis and is suitable for kinase assays, 
suggesting that enzymes are in their native form. For the TPAA a total volume of 
100 µL T-PER containing extracted proteins was required. T-PER in its normal form is 
a clear solution, not absorbing in the required wavelength of 660 nm. After the blank 
processing (no tissue extracted) high absorption values were observed. A dilution 
series of T-PER was used to define, if a lower amount of the reagent reduces the 
interfering absorption. The absorption of T-PER could be reduced to 0.1 with a high 
dilution (1 µL T-PER and 99 µL H2O). With this dilution, the amount of extracted 
proteins was too small for the TPAA and thus not suitable. 
With this information tissue extraction, using a buffer consisting of PBS containing 1% 
(w/v) Triton-X-100 and 0.05% (w/v) SDS (at pH 7.5 and 3.2), was compared to T-PER 
extraction. Spleen tissue was used and extracted, the protein amount was quantified 
using a standard Bradford assay. The results of the extraction buffer at pH 7.5 were 
comparable to T-PER extraction (Figure 23 A). Extracting the proteins from porcine 
tissue showed that most proteins were extracted from liver and the fewest from muscle 
tissue (Figure 23 B). The protein amount (in mg/mL) was used to normalise the 
calculated protease activity values. 
In the TPAA the protein casein was used as substrate and released tyrosines were 
photometrically quantified (λ= 660 nm). Substance P could not be used as a substrate 
because it does not contain the amino acid tyrosine. The calibration curve of L-tyrosine 
(0.0055 – 0.11 µmol) was very reproducible and showed good linearity (N=3) (Figure 
24 B). Pancreatin is an extract of active proteases from bovine pancreas. It was used 
for positive control resulting in a protease activity of 0.78 ± 0.12 unit/mL (1 mg/mL in 
H2O). For negative control, this solution was heat denatured (20 min, 95 °C) and a low 
protease activity of 0.02 ± 0.01 unit/mL was calculated (Figure 24 C). 
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Figure 23: Use of extraction buffer in comparison to T-PER Tissue Protein Extraction Reagent T-PER 
(Thermo Scientific) is described to extract protein mildly and totally, in their active form A Extraction efficiency of 
suitable extraction puffer consisting of (PBS / 1% (w/v) Triton-X-100 / 0.05% (w/v) SDS) at pH 7.5 and 3.2 was 
tested. The extracted protein concentration is shown in the graph and showed good comparability for the 7.5 pH 
extraction buffer (N=3) B Frozen porcine tissues were cut into 30 µm slices, and six slices were collected for one 
extraction. Extraction was performed in 500 mg/mL wet tissue. Samples underwent five cycles of sonication and 
cooling on ice. The mixture was centrifuged, supernatant was collected and placed on ice. Protein quantification 
was done by Bradford assay. The extraction of the tissues resulted in differing protein concentrations, with the 
highest amounts for liver tissue, followed by kidney, spleen, pancreas and muscle (N=3). 
 
For protein extraction frozen porcine tissue was cut into 30 µm slices. Six of them were 
used for one extraction. Using the extraction buffer (500 mg/mL amount of wet 
tissue/volume of extraction buffer) and the developed TPAA method, tissue protease 
activities of porcine tissue were quantified based on absorption values (equation (1)). 
The highest activity was found for pancreas tissue (8.1 ± 0.8 U/mg, N=3) followed by 
tissue from spleen, liver, kidney and muscle (Figure 24 A). One has to note that the 
activity per mL (U/mL) did not show this order, as different amounts of protein were 
extracted from the tissue. The results confirmed the MALDI MSI observation that 
muscle showed low to no protease activity and pancreas the highest. The ranking of 
protease activity spleen > liver > kidney was also confirmed, compared to the survival 
potencies of the inhibitor-concentration experiment (Table 7). 
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Figure 24: Tissue activities, calibration curve and controls of TPAA To assess protease activity of the 
extracted proteins casein was placed at 37 °C. Then protein extract was added and incubated at 37 °C. The 
reaction was stopped by adding TCA and further incubated. Protein precipitate was separated by centrifugation. 
Finally, sodium carbonate and Folin & Ciocalteau’s phenol reagent were added to the supernatant and again 
incubated. For detailed volumes, concentrations and incubation times see method section 3.2.3. A The 
calculated activity values based on casein conversion to free tyrosine were shown in the table. When activity in 
U/mL was normalized on the extracted protein amount, the activity in U/g of the tissue showed same ranking of 
high activity in pancreatic tissue to low activity in muscle tissue. B The released tyrosine concentration was 
calibrated with high correlation coefficient. C As positive control native pancreatin solution (1 mg/mL in H2O), 
which is a protease extract from porcine pancreas, was used. Heat-denatured pancreatin solution was used as 
negative control. Both solutions were used in the TPAA and showed reproducible results. (N=3) 
4.1.6 Proteolytic activity of tumorous and non-tumorous tissue  
In the next step the methodology should be transferred to visualise endogenous 
protease activity to preclinical studies. Transgenic CEA424-SV40 Tag C57BL/6 J mice 
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develop spontaneous gastric carcinoma110,125. Earlier studies showed that the 
potassium adduct of the lipid PC(34:1) [M+K]+ = 798.54 is enriched in the tumour 
tissue114,126. Wild-type and tumour bearing tissue were first tested for selectivity (0 min, 
red spectra in Figure 25 A) in the mass ranges of substance P and its related peptides. 
Additionally, the tissue was checked for aging-related changes at RT (after 5, 10, 15 
and 60 min), as it is known that protease activity changes the peptidome of 
tissues124,127. None of the spectra showed interfering peaks for TCEA positive or WT 
tissues (Figure 25 A). Some signals could be observed in the vicinity of m/z 753.4, as 
most lipid signals occurred in the range of m/z 600 to 1100.  
 
 
Figure 25: Aging-related changes on TCEA positive mouse stomach could not be observed  TCEA positive 
and wild-type tissue was kept at RT (spectra colour: green 5min, blue 10min, orange 15min, black 60min) prior 
to MALDI matrix application compared to immediately used tissue (red spectra, 0min at RT). Shown are mean 
spectra of MALDI MSI. In the observed mass ranges for the resulting peptides (m/z 753.4, 900.5, 1104.6) and 
substance P (m/z 1347.7) itself no interfering signal was observed.  
 
For visualising endogenous tissue protease activity in mouse tissue, the incubation 
time was reduced to 30 min, as the fragments of substance P could be measured with 
higher intensity (Figure 26). Substance P distribution was shown in blue, the lipid signal 
PC(34:1)+K+ in red. The overlay on the left side showed that no substance P signal is 
left after 60 min of incubation. In addition, the signal intensities of the produced 
peptides were very low. With 30 min of incubation, all peptides could be visualised. 
Note that the intensity of substance P was reduced in regions were the tumour lipid 
marker was increased. With this reduced incubation time all further experiments were 
performed.  
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Figure 26: Incubation time optimisation for mouse stomach endogenous protease activity  When stomach 
tissues were incubated for 60 min during sample -preparation, no substance P signal was measured. The 
resulting peptides m/z 1104.6, 900.5 and 753.4 showed very low signal intensity. When incubating a consecutive 
slice for 30 min we were able to monitor the residual substance P signal. Further, the related peptide signals 
were visible as seen in the lower panel. 
Evaluation of tissue protease activity in TCEA-positive mouse stomach 
Tissue protease activity of TCEA positive mouse stomachs was first imaged on a 
MALDI TOF MS instrument, the rapifleX (Bruker Daltonics) (N=3). On one slice 
protease inhibitor mix was applied and results with and without PIM were compared. 
MALDI MSI ion distributions of the lipid tumour marker PC(34:1)+K+ 114, substance P, 
and its related peptides were shown for one representative replicate (Figure 27 A). The 
second replicate (replicate 2) was measured additionally using MALDI FT-ICR mass 
spectrometry. For statistical analysis of the ion distribution, spatially-aware shrunken 
centroid clustering was performed by D. Abu-Sammourh. By reducing the mass range 
for the calculation to m/z 798.54 ± 5 (798.54 ± 0.05 for MALDI-FT-ICR data) and 
restricting the cluster to r=2, two segments (tumour (T) and non-tumour (NT)) were 
calculated (Figure 27 B). The segments correlated well with the H&E annotation of 
tumour tissue and tumour-mucosa transition zone in all replicates, regardless of PIM 
application. Annotated muscularis and mucosa correlated with NT segment (Figure 28 
B). When segmentation was performed with the FT-ICR mass spectrometry data, the 
segmentation was sharper, probably due to higher mass resolution (Figure 28 A).  
For statistical analysis intensities of m/z 1347.73, 1104.59, 900.50 and 753.43 were 
extracted for each pixel of the segments T and NT (Figure 28 C) for both conditions 
+PIM (+) and –PIM (-). The intensities were log10 transformed for visualisation because 
of a wide spread of intensities. In the NT segment higher ion intensities of substance 
                                            
h The spatially-aware shrunken centroid clustering analysis had been performed by D. Abu-Sammour 
as described in Erich et al. (2019)115 
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P were found then in the T segment, regardless of PIM addition. Further, m/z 1104.6 
was increased in T segments, m/z 900.5 showed nearly no difference and m/z 753.4 
was increased in inhibited T+ segments (Figure 28 C). Regarding the segmentation, 
higher mass accuracy and resolving power improves the result, as less scattering was 
visible. FT-ICR MS CID fragmentation was used on the tissue to confirm the identity of 
the observed peptides. The intense signals m/z 1347.735, 900.504 and 753.435 were 
fragmented, and b-ion series in the MS/MS spectra indicate their origin from substance 
P (Figure 29). For m/z 1104.6 the accumulated intensity was below the required 
intensity for successful CID. These results substantiated the interpretation that tissue 
protease activity monitored by MALDI MSI showed differentially distributed activity. 
The activity seems to be higher in tumorous tissue and susceptible to PIM inhibition. 
 
 
Figure 27: MALDI-TOF data of TCEA-positive mouse stomachs Two cryosections of CEA424-SV40 Tag-
positive stomachs were melted onto ITO slides, one of which was covered with protease inhibitor mix (+PIM). All 
tissues were covered with substance P and incubated for 30 min at 37 °C. A For one representative tissue the 
MALDI MS ion images of the tumour lipid m/z 798.5 (PC (34:1) + K+), m/z 1347.7 (substance P), and peptides 
cleavage products (m/z 1104.6, 900.5, 753.4) were shown. Note that areas of highest concentration of m/z 753.4 
represent peptide wash-out outside the tissue. B The images showed an automated identification of tumorous 
(T) and non-tumorous (NT) tissue by segmentation with spatially aware shrunken centroid clustering for all three 
replicatesi 
                                            
i The spatially-aware shrunken centroid clustering analysis had been performed by D. Abu-Sammour as 
described in K. Erich et al115 
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Figure 28: MALDI-FT-ICR of TCEA positive mouse stomach The stomach of transgenic CEA424-SV40 Tag-
positive tumour-bearing mouse was dissected and immediately frozen. Two cryosections were melted onto an 
ITO slide, one which was covered with protease inhibitor mix (+PIM). All tissues were covered with substance P 
and incubated for 30 min at 37 °C. MALDI MSI was acquired with 50 µm spatial resolution on a SolariX FT-ICR 
instrument. A Showen on the left is the automated identification of tumorous (T) and non-tumorous (NT) by 
segmentation with spatially aware shrunken centroid clusteringj. The MALDI MS ion images of the lipid m/z 
798.54 (PC (34:1) + K+), m/z 1347.73 (substance P) and peptides cleavage products (m/z 1104.59, 900.50, 
753.43) are shown. Note that areas of highest concentration of m/z 753.43 represent peptide wash-out outside 
the tissue. MALDI-FT-ICR ion images have higher mass accuracy and sharper segmentation results than MALDI-
TOF images and also show the inhibitor mix’ effect on substance P cleavage and the production of truncated 
peptides. B After data acquisition slides were H&E stained, and tumour, mucosa, tumour transition tissue and 
muscularis were annotated. D For pixel-wise statistical analysis, intensities for m/z of substance P and resulting 
peptides were plotted for all pixels on a logarithmic scale. Scale bar is 2 mm. 
 
 
                                            
j The spatially-aware shrunken centroid clustering analysis and pixel-wise intensity extraction had been 
performed by D. Abu-Sammour as described in K. Erich et al115 
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Figure 29: B-ion series in MS/MS spectra of fragmented highly abundant peptides reveal stretches of 
substance P sequence  Using MALDI-FT-ICR tandem MS of those m/z was performed with optimised CID 
energies on tissue samples. The sequence of substance P (m/z 1347.735) RPKPQQ (m/z 753.435) and 
RPKPQQF (m/z 900.505) were fully sequenced and verified. 
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Influence of pH on tissue protease activity in gastric mouse tumour tissue 
As protease activity is prone to environmental tissue conditions like salt-concentration, 
pH and other co-factors, tissue protease activity was tested for its reaction to altered 
tissue pH. Tumour containing mouse stomachs were washed with ammonium formate 
(pH 3 and pH 7), and tissue protease activity was measured by MALDI MSI (N=3). 
Washing was performed by rinsing the tissue two times with 1 mL of the respective 
buffer128. It effectively removed potassium adducts of PC(34:1), as only the hydrogen 
adduct represented the tumour after washing (Figure 30 C). Its distribution was less 
confined, and more background signal in non-tumorous tissue was visible (Figure 30 
A). Regarding tissue protease activity higher signals of residual substance P were 
found, when tissue was washed with ammonium formate at pH 7 (Figure 30 B). It 
seems that the proteases responsible for the digestion of substance P required acidic 
pH, whereas the digestion was reduced with neutral pH. Intensity comparison of tissue 
without wash (std) and wash with ammonium formate pH 3 showed similar results. 
However, the spatial distribution of the substance P signal was indeed different. By 
washing the tissue, more substance P could be found in the tumorous tissue.  
 
 
Figure 30: pH changed the proteolytic activity of TCEA positive mouse stomach . Stomach tissue samples 
were washed with ammonium formate (pH 3, pH 7), dried under vacuum, and proteolytic activity was assessed 
A MALDI MSI of one representative tissue slice was shown. Ion distributions refer to substance P PC(34:1) + K+  
in the upper panel, +H+ in the lower panel. B The experiment was performed in triplicates and the TIC normed 
intensities of substance P were shown in the scatter plot. Substance P had the highest intensity in the tissue 
washed with ammonium format pH7. When washed with ammonium formate pH 3 the intensity of substance P 
was reduced as the standard procedure without washing. C The ratio of PC(34:1)+K+/PC(34:1)+H+ confirmed, 
that washing reduced the adduct formation. In addition, in the MALDI MSI, it was clearly visible, that the 
potassium adduct was only present in the unwashed tissue slice. Scale bar 2 mm; N=3. 
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Proteomics study of mouse gastric cancer tissue with focus on peptidases 
A proteomic study was performed to further investigate the difference of protease 
expression between tumourous and non-tumorous tissue. The first obstacle was the 
accessibility of pure tumour and non-tumour tissue. Therefore, TCEA positive mouse 
stomachs (N=3) were sliced on the cryostat. The whole slice was stored in vials 
labelled as TS (tumour-stomach). Further, MALDI MSI was acquired to localise the 
tumour (Figure 31). According to these results, the tissue was further sliced manually 
(white line, Figure 31). Tumour samples (T) and non-tumour samples (NT) were 
manually excised and used for quantitative proteomic analysisk. This preparation was 
not ideal for gaining pure tumour tissue, but suitable for low sample amounts as in 
mouse stomach. In addition, WT stomachs were sliced and used as reference tissue 
(N=3). 
 
 
Figure 31: MALDI MSI of TCEA positive mouse stomachs to localise the tumour The MALDI MSI has been 
performed prior to the separation of the tissue to locate the tumour tissue. The signal of PC(34:1)+K+ is highly 
enriched in the tumour. Shown are the three biological replicates used in the proteomics study (A, B, C). The 
white line shows the separation of tissue to gain tumour (T) and non-tumour (NT) samples. 
 
In total 3394 proteins were identified and quantified using label-free quantification 
(LFQ). By filtering the UniProt database search (organism:mouse, reviewed:yes, gene 
ontology:proteolysis GO:0006508) for enzymes with “enzyme class” of peptidases 
(EC3.4.-.-), 537 proteases were found. From all identified proteins 104 were thus 
identified to be peptidases. Principal component analysis (PCA) and hierarchical 
                                            
k Bottom-up proteomics experiments were performed by Torsten Müller at the German Cancer Research 
Center (DKFZ) in the group of Prof. Dr. Jeroen Kriijgsveld as described in K. Erich et al. (2019)115 
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clustering (HC) were accomplished for all identified proteinsl (Figure 32). When 
statistical analysis was performed on all identified peptidases, the PCA showed 
independent groups for WT, NT and T tissue. Component 1, which describes the 
biggest difference in the samples, showed the highest variance between WT and T 
sample. NT data points were spread in between those two. HC showed grouping of 
WT and NT tissue, with one origin. A second group consisted of T was found. 
Therefore, the NT sample displayed more similarities to WT tissue, as to tumour and 
tumour-containing tissue. 
 
Figure 32: Statistical analysis of proteomic results for all identified peptidases without TS samples A In 
the proteomic analysis of wild-type stomach (WT), separated tumour (T) and non-tumour (NT) tissue samples 
3394 proteins were identified. In the UniProt database there are 537 hits for proteins in the organism: mouse 
having the GO-term: proteolysis (GO:0006508) and an EC number of 3.4.-.-, representing peptidases. The 
comparison showed that 104 peptidases were identified. B, C Using the information of all identified proteins and 
their (label-free quantified) LFQ intensity for hierarchical-clustering (HC) and principal-component-analysis 
(PCA) the three tissue groups can clearly be separated. 
 
Statistical analysis based on the identified proteases showed also a separation in PCA 
space and in HC analysis. In sum, these results indicated that the expression levels of 
proteases are different between tumour and non-tumorous tissue, with some 
uncertainty about the state of the non-tumorous tissue.  
                                            
l Statistical analysis were performed by Torsten Müller at the German Cancer Research Center (DKFZ) 
in the group of Prof. Dr. Jeroen Kriijgsveld as described in K. Erich et al. (2019)115 
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Using limma statistics129 the fold-change values were used to identify peptidases that 
differ significantly between T and NTm (Table 8). The most dominant differently 
expressed protease was the proteasome subunit beta type-10 (EC 3.4.25.1). Further, 
comparison of T and WT was performed. Here, two differentially expressed proteases 
were found: Caspase 7 (EC 3.4.22.60) and Endoplasmic reticulum aminopeptidase 1 
(Q9EQH2) (Table 9).  
 
Table 8: List of significantly changed proteases comparing tumour and non-tumour-tissue In the statistical 
analysis of T against NT samples two peptidases were identified to be weakly but significantly changed (fold-change 
>1.5 or <-1.5 and p-value <0.05).  
UniProt Protein name 
Nb. of 
identified 
peptides 
Sequence 
coverage 
% 
EC 
number 
MEROPS 
ID 
Q9EQH2 
Endoplasmatic reticulum 
aminopeptidase 1 
11 14 3.4.11.- M01.018 
P97864 Caspase-7 4 17.5 3.4.22.60 C14.004 
 
Table 9: List of significantly changed peptidases comparing tumour and wild-type-tissue In the statistical 
analysis of T against WT samples 22 proteases were identified to be significantly changed (fold-change >1.5 or <-
1.5 and p-value <0.05). From those 22 identified proteases, 14 are described as peptidases with EC 3.4.-.-. Further 
enzymes belong to the class of Hydrolases, Acetyltransferase and Glycosyltransferase.  
UniProt Protein name 
Nb. of 
identified 
peptides 
Sequence 
coverage 
% 
EC 
number 
MEROPS 
ID 
O35955 
Proteasome subunit beta 
type-10 
3 18.7 3.4.25.1 T01.014 
O55234 
Proteasome subunit beta 
type-5 
8 28.8 3.4.25.1 T01.012 
P07146 Anionic trypsin-2 2 12.2 3.4.21.4 S01.064 
P18242 Cathepsin D 11 31.7 3.4.23.5 A01.009 
P20918 Plasminogen 9 13.5 3.4.21.7 S01.233 
P28076 
Proteasome subunit beta 
type-9 
2 8.7 3.4.25.1 T01.013 
P70398 
Probable ubiquitin carboxyl-
terminal hydrolase FAF-X 
16 7.2 3.4.19.12 C19.017 
P97864 Caspase-7 4 17.5 3.4.22.60 C14.004 
Q6A4J8 
Ubiquitin carboxyl-terminal 
hydrolase 7 
10 11.2 3.4.19.12 C19.016 
Q6P1B1 Xaa-Pro aminopeptidase 1 6 11.2 3.4.11.9 M24.009 
Q80W54 
CAAX prenyl protease 1 
homolog 
5 15.8 3.4.24.84 M48.003 
Q9CR35 Chymotrypsinogen B 6 31.6 3.4.21.1 S01.152 
Q9CYN2 
Signal peptidase complex 
subunit 2 
13 53.5 3.4.-.- - 
Q9D7R7 Gastricsin 7 18.4 3.4.23.3 A01.003 
                                            
m Statistical analysis were performed by Torsten Müller at the German Cancer Research Center (DKFZ) 
in the group of Prof. Dr. Jeroen Kriijgsveld as described in K. Erich et al. (2019)115 
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4.1.7 Proteolytic activity of human gastric biopsy samples 
Tissue protease activity in human gastric biopsy 
To conclude this proof-of-concept study the potential of the method was evaluated for 
its translation into clinical research. Sections of gastric biopsy with substance P were 
incubated for 30 min and MALDI-TOF MSI (resolving power R ~10,000; mass accuracy 
< 30 ppm) as well as MALDI-FT-ICR MS images (resolving power R ~100,000; mass 
accuracy < 3 ppm) at 20 µm spatial resolution were acquired. Notably, low protease 
activity in muscular tissue was consistently found in porcine skeletal muscle (Figure 
12), mouse muscularis mucosae and muscle in human gastric adenoma (Figure 33). 
In analogy with the mouse tumour-mucosa transition zone after 30 min of incubation 
the substance P cleavage product m/z 753.4 was enriched in a similar zone in the 
human adenoma. The same was true for the transient accumulation of m/z 900.5 in 
glandular gastric mucosa (Figure 33). These results were obtained by MALDI-TOF and 
MALDI-FT-ICR mass spectrometers. With higher spatial and mass resolution the 
image quality was improved. 
 
 
Figure 33: Human gastric adenoma biopsy showed lower protease activity in muscularis than 
surrounding glandular tissue  Gastroscopic biopsy was taken and immediately frozen to -80 °C. Two 
cryosections were prepared, of which one was immediately covered with protease inhibitor mix. Further two 
tissue slices were covered with substance P and incubated for 30 min at 37 °C. MALDI MS images were acquired 
using MALDI-TOF instrument (50 µm spatial resolution, RP=10 000, mass accuracy < 30 ppm) and MALDI-FT-
ICR instrument (20 µm spatial resolution, RP=100 000, mass accuracy <3 ppm). H&E staining was performed 
on an adjacent section. Substance P signal (green) was still visible after 30 min in muscle tissue, whereas the 
glandular tissue prominently displayed the cleavage product at m/z 900.5 (purple). The same distribution was 
found in FT-ICR MS measurement, albeit with higher mass accuracy. White scale bar = 1 mm  
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Comparison of proteolytic activity of human adenoma and normal gastric 
biopsies 
It was now the idea to test human biopsies of gastric tumour tissue and normal gastric 
tissue for their tissue protease activity. Two patients who underwent gastroscopy were 
chosen by our partner Dr. Tobias Gropp (Department of Medicine II, Medical Faculty 
Mannheim, Heidelberg University). Multiple biopsies (Ø about 5 mm) were taken from 
tumorous tissues (adenoma) and from tissue far away from tumorous tissue (normal). 
Biopsies were immediately frozen to -80 °C and further processed in our lab. Each 
biopsy was sliced for H&E staining and histological annotation performed by Tobias 
Gutting (Department of Medicine II, Medical Faculty Mannheim, Heidelberg University). 
Only samples with confirmed tissue type (adenoma or normal mucosa tissue) were 
selected for further analysis. Three slices of each biopsy were placed on an ITO-glass 
slide for MALDI MSI. One slice was used for selectivity assessment and therefore not 
further processed (native). The second tissue slice was covered with PIM and 
substance P, whereas the last slice was only covered with substance P. The 
experiments were performed two times with two different incubation times (30 min and 
15 min). Using DHB MALDI matrix acquisition was performed on MALDI-TOF MS 
rapifleX (Bruker Daltonics). The distribution of the substance P signal and the resulting 
peptide signal m/z 900.5 was shown in Figure 33. Other resulting peptides were below 
the sensitivity level of the instrument. It was observed that no interfering signals were 
present in the native tissues regarding the mass range of substance P and m/z 900.5. 
For patient 1 no clear difference in signal intensities for adenoma and normal tissue 
can be found. In patient 2, a difference was observed. Further, the ion distribution was 
consistent in the groups of tissue type and patients.  
With 15 min incubation few m/z 900.5 signal intensity was present, whereas after 
30 min incubation, the peptide was clearly present. This was in line with the dynamic 
production of this peptide on porcine tissue, where no significant difference with and 
without PIM could be found after 15 min (Figure 20). Furthermore, the signal is more 
intense without PIM application on normal tissue. White pixels represented the co-
localisation of substance P (green) and m/z 900.5 (pink), so both peptides were present 
in the same pixel. This was clearly visible in patient 2 and slightly in patient 1. In 
contrast, adenoma tissue did not show m/z 900.5 without PIM application. There were 
two possible reasons for that: It might have been, that the proteases present in tumour 
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did not produce this peptide, or the proteases were highly active, and the peptide was 
already further degraded and not present any more.  
During the 30 min incubation experiment, in normal tissue more m/z 900.5 and less 
substance P signal were found. This could be interpreted as an ongoing tissue 
protease activity and ongoing digestion of substance P. Further, the peptide m/z 900.5 
was present in the adenoma samples of patient 1 without PIM, and also slightly in 
adenoma samples of patient 2. Concluding that the peptide was produced in adenoma 
tissue, but in a transient state, which is not ideally covered at 30 min of incubation time. 
Further, the two cases of adenoma (-PIM) were not operating similar, as in patient 1 
intense signal of m/z 900.5 can be found.  
Overall, the expectation of different tissue protease activity of tumorous and normal 
biopsies was supported by these data. It was not answered, if high tissue protease 
activity could be correlated with a low presence of m/z 900.5. It can be concluded, 
however, that on human biopsies the degradation of substance P and production of 
m/z 900.5 was sensitive to PIM. Thus it was feasible that a dynamic proteolytic process 
can be observed. Studies with optimized and standardised workflows and higher 
patient numbers are required for answering clinical questions.  
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Figure 34: Human gastric adenoma biopsy showed low protease activity in muscularis compared to 
surrounding glandular tissue  Gastroscopic biopsies were taken of two patients and immediately frozen to -
80 °C. Three cryosections were prepared, of which one was immediately covered with protease inhibitor mix 
(+PIM). This and one more slice were covered with substance P. One slice was not covered at all (native). This 
setup was prepared two times and incubated for 30 min and 15 min (37 °C, 95% humidity). MALDI MS images 
were acquired using MALDI-TOF instrument at 50 µm spatial resolution. H&E staining was performed on the 
same section after washing away the MALDI matrix. Tissues were annotated based on the H&E stain into normal 
and adenoma tissue. Ion distributions of substance P (green) and m/z 900.5 (pink) are shown. If the masses co-
localise the colour turned white. After 15 min incubation higher intensity of residual substance P was detected, 
whereas after 30 min, the resulting peptide was more dominant. Adenoma tissue and normal tissue show 
different behaviour regarding the degradation of substance P. 
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4.2 Part II - Development of scores for the assessment of quality 
factors using FFPE tissue digest 
A method that should finally be applied for diagnostics or prognostic evaluation in 
clinics requires high standardization with guaranteed reproducibility and repeatability. 
In addition, the use of quality parameters is a prerequisite for routine clinical 
application. Score-based method development in MALDI MSI is still a rare occasion. 
The use of MALDI MSI however, can increase the understanding of molecular basis of 
tissue and thus give insights into mechanisms of disease62,130,131. MALDI MSI is a 
method with great potential in drug development126,132,133, disciplines like studying plant 
organism134 or textile surfaces135, but also in clinical pathology62,64,136. Present 
publications show the use of MALDI MSI for therapy response prediction137–139, 
disease classification140–142 and assessing tumour heterogeneity143,144. 
As the method is still young (initially developed for proteins in the late 1990s)145,146, 
MALDI MSI has deficits of quality criteria and validation criteria compared to standard 
analytical methods147–149. Quantitative LC-MS/MS methods, for example, are defined 
as reliable, if specificity, selectivity, accuracy, precision, recovery and reproducibility 
are fulfilled. Even the accepted range is defined in CV%-values (< 10%)150. Further, 
the positive and negative controls as well as blanks are a prerequisite in LC-MS/MS 
and should be added to MALDI MSI workflows as well. 
In general, MALDI MSI requires distinct sample preparation, namely the application of 
MALDI matrix on fresh frozen tissue. The sample condition itself defines which steps 
are required to make the tissue accessible for the matrix co-crystallisation. Frozen 
tissue is vulnerable to temperature changes during excision and sample storage. In 
contrast FFPE tissue is stable over long storage time periods at RT. The preparation 
of FFPE tissue for MALDI MS require the removal of paraffin and retrieval of tissue 
antigens. Further, a digestion steps is necessary to cut proteins into small pieces, as 
only molecules up to 20 kDa are accessible in MALDI MS151. Regarding the law of error 
propagation such multiple handling processes also introduce variability, which stresses 
even more the need for unbiased score-based method development for FFPE tissue 
digestion in MALDI MSI. 
4.2.1 Score for digest efficiency DE% 
The use of a positive control in analytical methods shows a high-quality standard. So 
far this was uncommon in MALDI MSI. Heijs et al. used an isotopically labelled peptide 
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in analogy to their target molecule to investigate the digestion of their target protein on 
frozen rat brain95. The use of a protein as a positive control is remarkably new. During 
the tests for a suitable candidate as positive control protein (myoglobin and cytochrome 
c) also the condition was tested. Both proteins have a molecular mass within the 
MALDI-assessable mass range <20 kDa (MWmyoglobin = 16.7 kDa, MWcytochrome c = 
12.4 kDa) and could be measured in linear positive mode. To simulate the digestion 
condition of endogenous proteins myoglobin and cytochrome c were pipetted (3x 1 µL 
of 100 µM protein in H2O) on tissue and on an ITO glass slide before (“digest”) and 
after incubation (“no-digest”). As digestion of the proteins with trypsin produces smaller 
peptides, the spots were additionally measured in reflector positive mode. In Figure 35 
A and B, MALDI MSI and mean spectra of a representative spot were shown for 
myoglobin and cytochrome c on an ITO slide and on tissue, respectively. For 
cytochrome c pipetted on the ITO slide lower signal intensity of the protein was found 
in the digested spot compared to the not digested spot. For myoglobin this behaviour 
was not observed in a reproducible way (Figure 35 A). Looking at the mean spectra of 
cytochrome c, a high number of digested cytochrome c signals (see lower mass range) 
were present, and these signals were not visible in the undigested spots. When 
proteins were pipetted on the tissue (FFPE preserved human liver, processed as 
described in material and methods) a reverse effect was visible (Figure 35 B). By taking 
the mean intensity of the protein signals in the pipetted spots and calculating the DE% 
(according to equation (2)) it became obvious that cytochrome c on ITO slide gave 
most reproducible results and DE% about 95 % (Figure 35 C). As DE% was a new 
score sequence coverage and the number of matched peptides were also observed. 
These two values were commonly used to evaluate the efficiency of digestion 
procedures152,153. Cytochrome c pipetted on the ITO glass slide gave the best result 
with sequence coverage of about 60 % and the highest number of matched peptides 
(Figure 35 D). 
In order to monitor the digestion procedure using trypsin in MALDI MSI cytochrome c 
(100 µM in H2O) pipetted on ITO glass slides revealed as the most reliable positive 
control.  
 
Results – part II – scores for standardisation 
73 
 
Figure 35: Cytochrome c on ITO slide revealed best digestion results The proteins myoglobin (green) and 
cytochrome c (purple) were tested for their use as positive control digestion spots (on ITO slide or on tissue). A 
MALDI MSI showed protein signal pipetted on ITO slide of three spots in undigested and digest condition. The 
spectra represent mean spectra of one spot. Signal intensity in the digested spots was reduced with better 
reproducibility for cytochrome c. B MALDI MSI showed protein signal pipetted on liver tissue of three spots in 
undigested and digest condition. The spectra represent mean spectra of one spot. The intensity in the digested 
spots was not reduced. C The graph shows the calculated DE% values for both proteins and conditions. D 
Sequence matches and peptide coverages were calculated by using BioTools (Bruker Daltonics).  
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In the comparison of the described five methods (see Figure 6) for FFPE tissue 
digestion the score DE% of cytochrome c could only be calculated for three of them. 
Those were method I, III and V, as these are the ones using DHB as MALDI matrix. A 
measurement of the native protein was not possible with the MALDI matrix HCCA. 
Comparing the achieved DE% values revealed that method III has the highest value 
with the lowest standard deviation (Figure 36).  
 
 
Figure 36: Decrease of cytochrome c molecular ions is used to calculate digest efficiency (DE%) This 
calculation was possible only for methods 1, 3 and 5 that use 2,5-dihydroxybenzoic acid (DHB) matrix which 
enables measurement of cytochrome c molecular ions [M+H+]+, [M+2H+]2+ and [M+3H+]3+. As shown in the bar 
chart, method 3 resulted in the highest DE% and the lowest variability. The spectrum shows cytochrome c 
molecular ions of method 3 replicate 1 as an example - with the undigested measurement region in the upper 
spectrum and the digested region in the flipped spectrum. None of the three cytochrome c molecular ions could 
be detected in the digest, which corresponds with full digestion.  
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4.2.2 Scores for repeatability and homogeneity 
Repeatability or reproducibility in MALDI mass spectrometry has been analysed very 
rarely with the focus on MALDI matrix application103,154,155 or protein profiling in body 
fluids (reviewed by Albrethsen et al.156). Few studies evaluated their method for 
repeatability in tissue digestion experiments. De Sio et al. and Heijs et al. used peak 
counting to identify a highly repeatable method for digestion of human FFPE brain and 
frozen rat brain, respectively93,95. Diehl et al. used visual inspection of PCA and manual 
organ-structure counting (by different independent researchers) to find the best 
method for digestion of FFPE and frozen rat brain tissue96. To identify the preparation 
steps that induce variance and to develop an SOP Oetjen et al. used fractional 
factoring design of experiments (DoE) and the measure of spatial chaos98. 
 
When applying the commonly used peak-counting (picking peaks with S/N >3) to our 
dataset of five different methods on two individual FFPE tissues (human GIST and 
liver) for all three replicates, we were not able to distinguish which method gave the 
best result (Figure 38 and Figure 39). By adding a colour-coded grouping of the picked 
peaks to three mass ranges (small 500-700 Da, medium 700-2000 Da, big 2000-
5000 Da) it became visible that in the small mass range the number of peaks was very 
stable and ranged from 7 to 13 peaks. The most peaks were discovered in the medium 
mass range which covered the resulting peptide size after tryptic digest157. The highest 
variance was visible in the big mass range. Neither peak counting nor the applied mass 
range grouping revealed a method being highly repeatable. Therefore, it was our 
declared aim to develop easily computing and user-independent scores for evaluating 
repeatability. To accomplish that comparison of mean spectra within one tissue (judged 
to be >98% homogeneous) for homogeneity analysis and between replicate runs for 
repeatability analysis had been performed. The comparison was performed by 
introducing the novel use of correlation coefficient R2 and log2-fold-changes calculated 
by merged peak lists of mean spectra. All mean-spectra analysis were performed with 
commercially available software. Depicted in Figure 37 is the derivation of the extracted 
values for homogeneity analysis. The intensities for three mean spectra were 
compared pair-wise (a/b, b/c, c/a), and three R2 values calculated. In the same way 
comparison and fold-change calculations for each m/z value were done. Because of 
the use of homogeneous tissue the variability could only be introduced by the 
preparation of each method. In a homogeneous method the fold-change spread 
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(natFC, equation (3)) is expected to be very small. To sum that, a high R2 and a low 
natFC value accounted for a homogeneous tissue preparation. 
 
 
Figure 37: Derivation of natFC and R2 for homogeneity analysis For the homogeneity analysis mean spectra 
of three ROIs in one tissue are extracted using mMass software. Based on one common peak list intensities are 
exported by using Scils Lab. Fold-change calculations and correlation analysis were performed in Excel. This 
analysis resulted in three values for one tissue, which were all considered for the judgement of the homogeneity. 
If tissue homogeneity was high, R2 was also high and natFC was low. 
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Figure 38: Number of picked m/z-values for each method and each replicate on GIST Peaks were picked based on finding local maxima and compared to the noise baseline, 
which was estimated using the Supersmoother algorithm as implemented in the “MALDIquant” R package with  𝑆/𝑁 > 3. Furthermore, columns are split into three parts: red 
representing the signals from 500-700 Da, orange from 700-2000 Da and green from 2000-5000 Da 
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Figure 39: Number of picked m/z-values for each method and each replicate on LIVER Peaks were picked based on finding local maxima and comparedto the noise baseline, 
which was estimated using the Supersmoother algorithm as implemented in the “MALDIquant” R package with 𝑺/𝑵 > 𝟑. Furthermore, columns are split into three parts: red 
representing the signals from 500-700 Da, orange from 700-2000 Da and green from 2000-5000 Da. 
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When comparing the R2 and natFC for homogeneity analysis between the five 
compared methods, it was obvious, that method III and IV have high R2 and low natFC 
values with the lowest variability between the three performed replicates (Figure 40). 
On GIST tissue (Figure 40 A), the difference to the other methods is more obvious than 
on liver tissue (Figure 40 B). 
 
 
Figure 40: Scores for statistical analysis of homogeneity of FFPE tissue processing and sample 
preparation Histomorphologically homogeneous GIST and liver FFPE tissue was processed and analysed by 
MSI according to five different methods [N=3 replicates]. Three regions of interest (ROI; ~110 pixels each) per 
tissue section were selected and statistically evaluated using SCiLS lab and R software. A, B (A, GIST FFPE 
tissue; B, liver FFPE tissue) Coefficients of determination R2 (filled circles) were calculated for all m/z with S/N 
> 3 extracted from mean spectra of the three ROIs (1 versus 2, 2 versus 3, and 3 versus 1) for all replicates with 
all methods. Furthermore, log2 fold-changes for the identical m/z values between the same ROIs (1 versus 2, 2 
versus 3, and 3 versus 1) were calculated for all replicates and all methods. The natural fold-change value 
(natFC; open circles) represents either the 95th or 5th-percentile of fold-changes in the box-and-whisker plot 
(whatever is higher). Prior to all calculations spectra were median-normalized and square root-transformed to 
minimize variability and the influence of highly intense signals. Please note that methods 3 and 4 resulted in 
consistently high R2 and low natFC for both tissues.  
 
With a small adaptation, the same scores can be calculated to evaluate repeatability. 
Instead of comparing three ROIs within one tissue (Figure 37), three ROIs from three 
individual experiments were compared (Figure 41). For GIST tissue again, method III 
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and IV displayed high R2 and low natFC values (Figure 41 A). In the case of liver tissue 
only method III showed high R2 values (Figure 41 B). These results suggest that 
method III showed the best repeatability and homogeneity behaviour. 
 
 
Figure 41: Score-based analysis of inter-day repeatability indicates that prolonged incubation time 
minimizes variation Histomorphologically homogeneous GIST or liver FFPE tissue was processed and 
analysed by MSI according to five different methods. For assessment of inter-day repeatability, three full 
technical replicates with three selected ROIs each were analysed per tissue. A, B (A, GIST FFPE tissue; B, liver 
FFPE tissue) Coefficients of determination R2 (filled circles) and a single natFC value (open circles) were 
calculated for all m/z with S/N > 3 extracted from mean spectra of the three replicates (1 versus 2, 2 versus 3, 
and 3 versus 1) for all methods. The single natFC value is the highest absolute value of all 95th and 5th percentile 
fold-changes for the three replicates. Note that the most consistent and highest R2 and lowest natFC were 
observed for method 3 (with prolonged incubation time) in both tissues. 
 
So far, all results were obtained on mean spectra. For confirmation computationally 
intensive pixel-wise-analysis (comparing 1000 pixels for homogeneity analysis and 
3000 pixels for repeatability analysis) was done by my college Denis Abu-Sammour. 
The results are summarised in Erich et al. (2016) and they confirmed the mean-spectra 
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analysis (Figure 42). The mean of R2 values was the highest in method III (close to 1), 
and additionally the spread of the values, reflected by the inter-quartile-range IQR, was 
small. Additionally, this reflected a high similarity between the compared pixels. The 
scatter-plot of fold-change values now comprised all the calculated fold-changes 
(instead of natFC). Here IQR reflected the similarity of the intensities. A small IQR 
accounted for similar fold-change values (scattered around 0) and thus similar 
intensities in the compared spectra. 
 
 
Figure 42: Scores calculated on pixel-wise comparison for homogeneity and repeatability analysis (A, 
GIST FFPE tissue; B, liver FFPE tissue) In pixel-wise analysis using R statistical computing language, individual 
spectra belonging to a given tissue, replicate and method (all 3 ROIs) were pooled together and the boxplots 
were generated by finding R2 and fold-changes (FC). For homogeneity analysis 1000, and for repeatability 
analysis 3000 different and randomly chosen combinations of the pooled spectra were used. Hence, good 
homogeneity were attributed to samples that had a small interquartile range (IQR), that showed consistency 
between the replicates and that had high R2 and low FC. The pixel-wise homogeneity analysis indicated superior 
homogeneity with methods III and IV for R2, whereas all methods showed similar behavior with FC. Again, the 
pixel-wise repeatability analysis indicated the superiority of method III for R2 and FCn. 
                                            
n Calculations for pixel-wise comparison had been performed by D. Abu-Sammour as described in Erich 
et al. (2017)120 
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5 DISCUSSION 
5.1 Optimised substrate application with water sensitive paper test 
It has been discussed several times that the homogeneous application of MALDI matrix 
followed by effective extraction and co-crystal formation is the most important step to 
assure good spatial resolution and high-quality spectra146,154,158. This fact holds true 
for any deposition of liquid on tissue, in our case the application of the tracer substrate 
substance P. For matrix applications the overall CV% of pixel-wise signal intensity and 
the mean intensity of the spectra were used as quality criteria for homogeneous 
application154. Further, the matrix crystal size is a measure of a good application, as 
smaller crystals assure lower spatial resolution. The size of the crystals can be 
measured by light or electron microscopy159–161. Smaller crystal sizes could be 
achieved by applying the matrix in dry sprays (low organic solvent amount and/or high 
temperature). This, however, has a negative effect on the extraction of the analytes 
from tissue and therewith results in poorer sensitivity. Mean ion intensity, CV% of pixel 
intensity or crystal size cannot be used with the application of an aqueous solution that 
contains a small molecule/peptide/lipid for normalisation162–164 or monitoring tissue 
digest95. For proper method optimisation an easily accessible and MALDI-acquisition-
independent measure for the solvent application is necessary. With the use of WSP 
the spray quality of aqueous solutions can easily be accessed and quantified by the 
mean grey value. The method has good potential to be used in quantitative MALDI 
MSI, when internal standards being structural analogues (e.g. deuterated molecule) of 
the substance of interest are sprayed to allow for relative quantitation165. The use of 
internal standards is one way to overcome ion suppression that is varying in different 
tissue regions and is also varying between different tissue types/organs166,167. WSP 
can additionally be used to routinely check for instrument performance, as spray 
devices often consist of capillaries and screw fittings that are prone to constipate. The 
dye rhodamine B is not universally suitable to test delocalisation effects. Note, that 
rhodamine B is soluble in water and alcohol and so does not represent all molecules 
in a tissue slice. One can assume that immobilised or lipid-soluble molecules are not 
affected by the application of an aqueous solution. It thus would have an effect on 
water-soluble molecules that are easily accessible in tissue compartments. For this 
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scenario rhodamine B represents the affected subgroup of molecules and can be used 
for optimising spray parameter in favour of lateral diffusion. 
5.2 Mean spectra analysis is restricted to homogeneous tissue 
Latest literature from Taylor et al. showed that heterogeneous tissue can be 
responsible for differing ionisation and suppression effects in MALDI MSI. The 
suppression of olanzapine sprayed on brain tissue was evaluated calculating a tissue 
extinction coefficient. This calculation includes removal of peaks, segmentation, and 
clustering, thus is computationally intense and not calculable with commercially 
available software123. In contrast, ROI based analysis is feasible without much 
computational effort120. In this study brain tissue was initially included, but the 
morphology led to an inhomogeneous distribution of substance P signal in the control 
slide. As homogeneity was the prerequisite for a ROI based analysis of mean spectra, 
brain data has been excluded in further analysis. All other tissues showed a 
homogeneous distribution of the substance P signal in the control slide. The use of this 
control tissue for each time point enabled the comparison of the incubation time points. 
MALDI MSI acquisition settings require the adjustment of laser intensity and detector 
gain, optimised prior to each run168. The values depend on the current condition of the 
instrument (clean status of the ion source and detector), and on the preparation quality 
(tissue quality, matrix amount and crystallisation). Further, the instrument settings are 
directly related to the absolute value of intensity (a.u.), which makes the comparison 
of absolute values nearly impossible. That is the reason for the differing intensity scales 
between the time points in the MALDI MSI. Proper controls are required for a validated 
comparison of these values. For tissue protease activity the control signal intensity was 
undigested and therefore used as 0% DE%. Commonly used TIC or median 
normalisation does not serve the purpose of inter-day comparability. For that reason, 
in quantification studies internal standard is sprayed on tissues to make quantification 
possible162,165. In this study, the monitoring of several m/z values was intended, and so 
several internal standards would be required for absolute quantification. Further, there 
is no consensus which preparation technique is the best for absolute quantification, 
and this was beyond the scope of this study169. Relative quantification related to the 
control tissue slices is the most elegant solution for the verification of tissue protease 
activity.  
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5.3 Observation of C-terminally cleaved substance P peptides 
Starting with the tracer substrate substance P (undecapeptide), only C-terminally 
cleaved peptides were observed, dominated by the hexa-, hepta- and octapeptide 
(Table 6). The digestion process is a first order sequential multi-step reaction, 
especially, when the peptide products of exopeptidases activity was observed170. The 
transient production and further degradation could be a reason for low intense signals 
of the decapeptide and nonapeptide, while the further digestion products were 
dominant. Yi et al. spiced isotopically labelled peptides into human plasma and serum 
samples. The researchers observed their digestion of the peptide and a final 
decreased of the digestion products in a four hours timeframe170. The study at hand 
covers a larger time frame, but also showed a decrease of the digestion products down 
to complete disappearance. Due to the fact that substance P is a unique peptide, there 
seems to be no biological explanation, why the active exopeptidases should cleave 
only from C-terminus. It is far more likely that MALDI ionisation process favoured the 
C-terminally cleaved peptides. It is known that the gas-phase basicity of amino acids 
is a requirement for ionisation171,172. The amino acids arginine (R) and lysine (K) fulfil 
this requirement. Peptides containing these basic amino acids can thus be protonated 
and measured in positive mode. In an ionisation comparison of MALDI to ESI, Nadler 
et al. showed that MALDI favoured a C-terminal arginine, while ESI prefered lysine as 
C-terminal amino acid. Both methods disfavoured cysteine (C), methionine (M) and 
tryptophan (W) containing peptides173. Now, looking at the amino acid sequence of 
substance P (RPKPQQFFGLM), the removal of the first N-terminal amino acid (R) 
already leads to a disfavoured amino acid composition for detection. A protonation, 
required for detection in MS, is then limited to the lysine in the peptide. Furthermore, 
the amino acid methionine is still present in the peptide chain. This could additionally 
explain the negative bias for the detection of N-terminally cleaved substance P 
peptides.  
5.4 Development of tissue protease activity assay 
An analogue method to measure tissue protease activity photometrically (TPAA) was 
developed to verify the results of MALDI MS tissue protease activity determination. 
With active protein extract from porcine tissues and casein as substrate, the released 
tyrosine was quantified and activity of the tissue was calculated.  
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The critical point in the assay exists in the extraction of proteins in their active form. 
Many protein extraction buffers contain detergents for cell lysis that also denatures 
proteins and proteases. Therefore, some effort was put in the extraction of active 
proteins by comparing a commercially available tissue protein extraction reagent (T-
PER) with a mild extraction buffer. According to supplier’s information T-PER should 
be able to extract whole protein content in the active form. Although T-PER is a clear 
solution, for the TPAA it was not suitable, as it produces high and thus interfering 
absorption values. T-PER consists of 25 mM bicine, 150 mM sodium chloride and a 
proprietary detergent. As Folin & Ciocalteu’s Phenol reagent is not selective for 
tyrosine, but rather react with total phenols and further non-phenolic reducing 
substances. The interfering absorbance might be produced by the reaction of Folin & 
Ciocalteu’s Phenol reagent with the unknown detergent174. The component bicine, an 
organic compound used as a buffering agent, could also react as a reducing agent and 
thus possibly reacts with the Folin & Ciocalteu’s Phenol reagent. The low detergent 
extraction buffer was therefore used for extracting active total amounts of proteins from 
tissue. The total amount will always be an approximation, as this non-selective 
extraction will still miss some proteins. Integral and peripheral membrane proteins, for 
example, required specialised extraction procedures175,176. For this study the activity 
of proteases was of interest, which are mostly secreted and present in the extracellular 
matrix (ECM)177,178 or expressed ubiquitously in lysosome179. 
5.5 Imaging of endogenous tissue protease activity by MALDI MSI in 
clinical routine 
So far high effort has been put on the development of photonic probes to monitor tissue 
protease activity45,180. Besides the requirements of a narrow excitation/emission 
spectrum, high chemical and photostability, non-toxicity, biocompatibility, 
biodegradability, and excretability181, specificity to an enzyme is also of high 
interest182,183. Now several lines of evidence suggested, that overall tissue protease 
activity can be measured with MALDI MSI: 
 Endogenous tissue protease activity was found to be time-dependent 
 A protease inhibitor mix (PIM) decreased tissue protease activity in a 
concentration-dependent manner 
 Not only the decrease of the tracer substrate but also increases of defined 
peptide products could be measured 
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Fluorescent chemical probes underwent great development in clinical applications with 
the goal of cancer imaging184. In future optical chemical probes should be used for 
diagnostics and pre-operative planning. They should be injected intravenously to find 
the location of tumorous tissue. To achieve this, dyes with enhanced properties and 
sensitive detection methods are required. Pre-operative images are made so far by 
positron emission tomography (PET) in combination with PET tracers. Garland et al. 
envision the use of one agent that has a PET tracer (for pre-operative planning) and 
can be used as an optical probe (for intraoperative decision making)185. As MALDI MSI 
required the use of tissue sections it cannot be used for in vivo surgical guidance. 
Another important clinical field, where optical chemical probes were of interest is the 
ex vivo surgical guidance. Cutter et al. were the first to apply activity-based probes 
topically on tumour tissue to identify the boundaries between tumour and healthy 
surrounding tissue in glioblastoma multiforme186. A recent study showed that 19% of 
women who underwent breast-conserving surgery received a re-excision187. Re-
excisions are required when post-residual cancer is found. During surgery 
intraoperative consultation (frozen section) of a pathologist is required to evaluate the 
excised specimen and give a preliminary result about the tumour margin. The 
pathologist will judge the tissue to be normal or indeed a tumour and, if the tissue is 
primary or metastatic. This procedure interrupts the surgery at the minimum of half an 
hour but also guides the surgeon to the complete tumour resection188. In addition, 
optical imaging probes and MALDI MSI could help to visualise tumorous tissue. 
Withana et al. developed a protocol for topical application of activity-based probes. 
This enables the imaging of enzyme activity on a cellular level50. The study in hand 
shows the ability to visualise protease activity using MALDI MSI. For both methods 
additional requirements need to be fulfilled to be evolved into a clinical application. (1) 
One next step for MALDI MSI is to study the specificity of the method by using specific 
protease substrates and their targets. It has already been measured by MALDI MS that 
proteolytic enzymes in brain tissue convert synthetic dynorphin B (neuropeptide) to N-
terminal fragments189. In 1962 Gross & Lapiere showed collagenolytic activity in 
tissue190 which later was referred to the enzyme family of matrix metalloproteinases191. 
Latest literature reviews the role of matrix metalloproteinases in invasion and 
metastasis of cancer192. Matrix metalloproteases degrade the extracellular matrix (and 
therewith allow cancer cells to invade surrounding tissue and enable tumour growth. 
Therewith the visualisation of MMPs activity can be of high interest for the analysis of 
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tumour surrounding tissue. Using a specific MMP substrate applied on a suitable tissue 
sample (containing an invading tumour and surrounding normal tissue) and by 
performing protease activity MALDI MSI could show the conversion products in a 
spatially resolved manner. As there are already developed ABPs for MMP activity the 
result should be compared to an optical image of a serial tissue section. This would 
show that MALDI MSI could also be used for targeted analysis, in contrast to the here 
shown universal protease activity analysis. (2) Further, it is absolutely required that 
large scale studies are performed where real patient tissue is analysed for protease 
activity using MALDI MSI and the gold-standard method for frozen sections193. This 
critical step will show how accurate MALDI MSI is to detect the tumour margins. (3) To 
bring this method to the clinics MALDI MSI equipment needs to be installed, 
specifically trained employee need to be hired and finally, the method needs to be 
covered by health insurance. All-in-all there is a long way to go. In the near future, the 
visualisation of protease activity with MALDI MSI will be restricted to basic clinical 
research and preclinical animal studies. 
Reduction of proteolytic activity due to post-mortem degradation of proteins 
Although in a preclinical experimental setup sampling storage conditions can be highly 
controlled, in a clinical setting this is hard to achieve. Scholz et al. analysed the impact 
of temperature on proteome and peptidome in liver and pancreas124. It showed that the 
post-mortem degraded proteins in the pancreas were, for example, Peptidyl-prolyl cis-
trans isomerase (Q9DCY1), type II cytoskeletal keratin 8 (P11679) and several 
regulation-related proteins. The dominant peptides that were digested were for 
example from insulin I and II C-peptides, glucagon and somatostatin. In brain tissue, 
the post-mortem degradation is dominated by cytoskeletal associated proteins194,195. 
For the developed visualisation of tissue activity using MALDI MSI, a post-mortem 
degradation of proteases would lead to reduced tissue protease activity. With respect 
to the results of the mentioned studies, it is very unlikely, that proteases are highly 
affected in post-mortem degradation. Still, in clinical setup it is highly recommended to 
set up sample logistics comprising cooled tissue transport and fast tissue evaluation, 
to minimise possible post-mortem degradation Further, it is recommended to perform 
such stability test when different tissue material is used, as the post-mortem 
degradome differs in various tissues124. 
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The use of students t-test in pixel-wise analysis 
For comparing complex and data-intense scenarios like for MALDI MSI an intensity 
box plot can help but has some drawbacks. When high amounts of pixels are used for 
comparison, also empty noise-containing pixels are included, which contain overall a 
very low TIC. Depending on the preparation, the tissue condition and the selected 
measurement region, this could massively influence the mean-calculation in a box plot 
and therewith the interpretation. Ideally, a threshold would be used to exclude such 
pixels from the analysis, as proposed by my colleague Denis Abu-Sammour120. A 
second pitfall is exposed to the number of data points, in such a pixel-wise analysis. It 
is the nature of MALDI MSI to produce high spatially resolved data, that contains 
thousands of pixels for one tissue slice (depending on the size of the tissue). If all pixels 
are included in the statistical analysis, as commonly performed with a Student's t-test, 
the number of values is very high (= number of pixel). Of course, having a low number 
of values would make a statistical analysis unreliable. With a very high number of 
values, nearly all mean-differences generated statistically significant results, even if 
the absolute difference of the mean is very low. Talking about significance then is 
problematic and the biological context of the values needs to be taken into account. To 
compare intensities statistically with segmentation, excluding-criteria and proper 
statistics196 are required and is far not implemented in commercially available software.  
5.6 A first idea of active proteases 
The pH test on protease activity showed that activity is preserved when wash with 
buffer at pH 3 was done. So one might conclude that acidic proteases are highly active 
in the analysed tissue. A protease-rich and acidic cell organelle is the lysosome, whose 
function is protein degradation. Lysosomal proteases are mainly aspartic-, cysteine, or 
serine- proteases, which are mostly ubiquitously expressed179. Still, the difference in 
intensity could result from the MALDI MSI pitfall of ion suppression in heterogeneous 
tissue123. The identity of varying protease expression between a tumour and non-
tumour could be clarified by using bottom-up proteomics. Therefore, forces were joint 
with researchers from the German Cancer Research Centre (DKFZ, Prof. Dr. Jeroen 
Krijgsveld). In a statistical comparison of expressed peptidases in T against NT, the 
most dominant differently expressed protease is the proteasome subunit beta type-10 
(EC 3.4.25.1). It is part of the proteasome and therewith an important part in protein 
degradation. Already 2002 the proteasome became a target for cancer treatment197. 
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Inhibitors like bortezomib were approved for cancer therapy of myeloma198. As non-
tumorous tissue is already impacted by the tumour cells the comparison of T and WT 
has been performed (Table 9). One differently expressed protease is Caspase 7 (EC 
3.4.22.60). Caspase-7 is a cysteine-protease involved in the cascade for apoptosis 
execution. Several caspases and their deregulated proteolytic activity direct to tumour 
growth18. To balance growth and degradation of cells, caspases are also targets for 
anticancer strategies199. Interestingly also Cathepsin D, which is located in the 
lysosome and ECM is differentially expressed in tumour and wild-type tissue. The other 
peptidases are located in nuclei, ECM or cytoplasm of cells. Further, the peptidases 
belong to catalytic classes of threonine-, serine-, aspartic-, cysteine-, and metallo-
proteases. The identification of the expressed peptidases does not reveal the identity 
of the proteases, that might be responsible for the degradation of substance P, as it is 
rather a combination of several proteases. But the analysis shows, that there are 
differentially expressed peptidases, that might be responsible for the different activities 
visualized in MALDI MSI. Note that the expression of a protein is not equal to its activity, 
rather confirms its presence. Especially for proteases the activation process from the 
inactive zymogens is a highly regulated process200,201.  
5.7 Assessment of the proteolytic tissue analysis in human gastric 
tumour 
For diagnosing gastric carcinoma, the standard procedure involves gastroscopy with 
collecting multiple biopsies, already when patients suffer from suspicious symptoms31. 
Although there are several non-invasive methods for diagnosing and staging of gastric 
cancer like confocal endomicroscopy202, NBI-magnifying endoscopy203 and 
endocytoscopy204, a histological study of biopsies is the current gold standard for 
histopathological examination of biopsies. However, biopsy seizing is time-consuming, 
bears the risk of bleeding and can cause submucosal fibrosis. As advanced gastric 
cancer has a poor prognosis, and early detection of resectable gastric cancer detection 
is of high interest205. To achieve this, proteases were targets of research as they are 
involved in early cancer development. The tumour microenvironment is extensively 
remodelled by proteases and change cell-cell and cell-ECM interaction, in favour of 
tumour growth angiogenesis and metastasis206. It has already been shown that in 
human gastric cancer cell lines the expression of cathepsin B, H and MMP2 is 
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elevated. Further, cathepsins and MMPs are described as potential biomarkers for 
early gastric cancer in mouse models42. 
In our analysis, slight differences in tissue protease activity of normal mucosa versus 
adenoma tissue could be visualised (Figure 34). The experimental preparation bared 
some problems. The slicing of such tiny tissue blocks (5-7 mm in diameter) requires 
high expertise with a cryostat. Additionally, two incubation times were prepared on 
different days. As between each preparation day, the tissue was kept at -80° and 
freshly frozen on metal tissue holder using CMC, the cutting angle differs. In the 
scenario of a tissue block (3 Dimensions) without a fixed orientation, this potentially 
results in different tissue compositions in the tissue slice. Therefore, differences in 
incubation times could also be related to differing slicing angles and therewith tissue 
composition (and size/form of the slice). Ideally, sequential sections are prepared with 
the same angle, to avoid this. It is not recommended to store already prepared ITO 
slides, as the tissue is melted on the slide and uncontrolled tissue changes could be 
introduced.  
Our study comprises two patients, which is of course not enough to solve a clinical 
question, but already shows experimental requirements, that need to be fulfilled for a 
bigger study. The observed difference in tissue protease activity of tumour and normal 
tissue is not consistent between the two patients. The normal mucosa tissue of 
patient 1 showed a similar pattern as the adenoma tissue of that patient. As mentioned, 
also tissue in the vicinity of a tumour suffer from tumour induced changes, that are 
histologically inconspicuous22,207. In the case of gastric tumour the non-tumour cells 
include stromal cells, and the stromal content is associated with poor prognosis for the 
patient208,209. This could be the reason, why the histologically declared normal tissue 
showed a tissue protease activity comparable to adenoma tissue. So how should 
normality or healthiness of the normal tissue be defined? The surgeon decides on basis 
of his expertise where to take the tumorous and normal tissue. Indeed, there are two 
definitions of normal tissue: nearby the tumour (“Tumor-nah”) and distant to the tumour 
(“Tumor-fern”). For bigger studies this should be defined. Ideally a healthy person 
should be the donor for the normal tissue, to circumvent the possible changes due to 
tumour-initiated changes. This leads to an ethical problem, as gastroscopy and taking 
biopsies without any medical incidence is not approved. Further, the location where 
the biopsies were taken are based on the stomach anatomy (cardia, fundus, body – 
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lesser or greater curvature, antrum or pyloric canal)210, and should be defined and 
noted.  
Apart from the inconsistency in normal and tumour-tissue it is also possible, that 
adenomas of different patients might have different protease content and therefore 
activity. Based on molecular classification gastric cancer is a very heterogeneous 
disease211. Personalised medicine takes not only the common phenotypes of 
adenoma, but also the individual genetic profile into account. This together defines 
clinical decisions regarding diagnosis, prognosis and therapeutics. Especially in cancer 
treatment, the effectiveness of the chemotherapeutics in hand with the minimised 
toxicity aims from individual predictive biomarkers. For gastric cancer there is a need 
for better methods to identify molecular targets, that look the same in conventional 
pathology, to clear the way for the development of specific drugs212. Proteases can be 
targets for the different states of gastric cancer and are insensitive in standard 
histological analysis. With more effort in the development of clinical studies based on 
MALDI MSI tissue protease activity monitoring such targets could be revealed. The 
spatially resolved monitoring of protease activity could potentially reveal also small 
local differences (<5 µm) which were not detected in methods that require 
homogenisation of the biopsy (expression analysis or protein extraction).  
5.8 Scores for FFPE tissue digests and evaluation of the best FFPE 
on-tissue digestion method 
Many studies showed the great potential of MALDI MSI in clinical pathology, reviewed 
by J. Kriegsmann in 2015213. But already there, the need for optimisation and 
standardisation of sample handling and preparation to minimise variability was 
claimed. Further M. Aichler and A. Walch postulated the need for high-quality studies 
in cooperation with pathological institutes to gain clinical relevance and improve tissue 
quality64. Due to the fact that the analysis of frozen material is prone to variability 
(simply due to temperature changes during transport or storage), MALDI MSI with on-
tissue digestion of FFPE tissue has been used for this initial studies on repeatability. 
Repeatability is defined as the variability that is induced when the same person 
repeats a measurement. The study in hand and two further studies evaluated the 
variability of FFPE conserved tissue preparation methods for MALDI MSI, and 
conclude that the multistep process is prone to introduce variability98,120,214. With this 
background latest research focussed on the translation of FFPE tissue preparation for 
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MALDI MSI into clinical studies and diagnostic/prognostic testing, by evaluating 
multicentre reproducibility. Reproducibility includes the variability that occurs if a 
method is repeated by different operators215. Buck et al. used multi-organ tissue 
microarrays from wild-type mice to study the impact of inter- and intracenter technical 
variation on the MALDI MSI of peptides and metabolites from FFPE tissue216. 
Reproducibility was described as dependent on the molecular class (peptides or 
metabolites) and the tissue type. This observation goes in line with the results 
presented in this study, where human liver and GIST tissue showed slightly different 
repeatabilities. Both studies use the correlation coefficient which is insensitive to 
multiplicative effects between the observed spectra. Despite the fact that the round-
robin study proposed first results that intercenter comparison improved multivariate 
classification, further explanations why peptide measurement is superior to metabolite 
measurement is required. In the study in hand, the most homogenous and repeatable 
preparation protocol for on-tissue digestion was identified. The main difference in 
preparative steps is a long incubation time of 18 h for the tryptic digestion, which has 
also been used by Buck et al resulting in surprisingly superior classification compared 
to the less complex metabolite preparation protocol216. It might be that the high 
reproducibility comes from a reached peptide limit, so all possible cutting sites are 
cleaved217. For specific applications in the future it needs to be clarified if the peptides 
of choice are still present. In plasma it is already shown, that different proteins have 
different optimum conditions for a full tryptic digest and these optimum conditions need 
to be defined for on-tissue digestion218. Note, that the maximum of detected peaks is 
not only limited by the amount of occurring peptides (=peptide limit), but also by the 
resolving power of the MALDI-TOF MS instrument (0.1 – 0.01 Da)102. After tryptic 
digestion with this mass resolution, a signal is present on nearly every mass, so the 
spectrum (700 – 2000 Da) is saturated. Peaks that occur here are most likely due to 
partial digestion, as fully tryptic peptides have a maximum mass of about 2000 Da. 
Each signal consists of several isotopic peptides, that cannot be resolved. Scherl et al. 
calculated that the in silico tryptic digest of human proteins (17 175 according to 
UniProt database, entered 2008) theoretically result in 2883 fully tryptic peptides in the 
mass range of 1200 – 1210 Da219.  
Contemporaneously to the round-robin study, Ly et al. performed a site-to-site study 
using ileum and jejunum from C57Bl/6 mice, human ovarian teratoma and TMA of six 
different human tumours prepared by on-tissue digestion for MALDI MSI. The on-tissue 
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digestion protocol was optimised in preparation time (reduced to 2 h at 50 °C with the 
use of saturated K2SO4 to maintain humidity220) but maintains spatial resolution. With 
the use of the standardised preparation protocol, the resulting segments were based 
on biological differences in the tissue, and not from the preparation centre, date of 
preparation or the initial location of the tissue. The authors claimed that trypsin 
deposition, digestion and matrix deposition cause preparation heterogeneity.  
 
The effort that had been made to address reproducibility can increase the acceptance 
of MALDI MSI to the clinics. It is an absolute requirement in clinical applications for 
diagnostic and prognostic tests that sample preparation is highly reproducible. 
Acquired results need to be stable over days and years, and also between clinical 
centres or operating clinicians/technicians. Predictive models will be reliable when the 
input data is of high quality in terms of low variability. To achieve the goal of MALDI 
MSI based diagnostics there is still a long way to go including studies with high sample 
number to set up a training model, define not only standardised preparation methods 
but also standardised data evaluation methods and develop scores for quality control 
(matrix deposition and digestion). For frozen samples additional optimisation and 
standardisation is necessary to reduce temperature variance and thus minimise post-
excision proteolytic activity. As long as those prerequisites are not fulfilled MALDI MSI 
will increasingly be used for pre-clinical and pharmaceutical research221. 
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6 CONCLUSION 
MALDI MSI provides unique advantages for analysing tissue specimen raising 
information that no other method can yield. Tissue-based research with MALDI MSI 
covers a broad spectrum of analytes like peptides and proteins, but also small 
molecules and lipids.  
The development of a spatially resolved tissue protease activity assay using MALDI 
MSI adds another group of biological targets to the wide range of MALDI MS accessible 
target molecules. In this study, the method was proven to be reliable and reproducible 
on porcine tissue and on the specific mouse model for gastric cancer. Time- and 
inhibitor-concentration dependency, and tracer related resulting peptides suggested 
the successful visualisation of a digestive processes. As proof-of-concept, a gastric 
tumour mouse model was used to visualise different protease activity in tumour tissue 
compared to surrounding tissue. Here MALDI-FT-ICR MS data gives superior results 
over MALDI-TOF MS data, with respect to spatially aware cluster analysis and peptide 
identification. The transfer to human biopsies is possible but requires further clinical 
validation studies with a higher number of participants, statistical analysis and 
pathologist expertise to classify the tumour subtype. It can be envisioned that the 
visualisation of protease activity can aid tumour margin detection during surgery. 
It is a final goal to improve MALDI MSI methods for the transfer to clinical applications, 
as it has been done for the ‘MALDI Biotyper’, which is already implemented in routine 
clinical use and provides the characterisation of bacteria. Molecular histology is so far 
in the field of pathology, where unique skills are required to identify tissue that 
represents patient’s disease. To bring MALDI MSI in routine diagnostic two aspects 
are absolutely inevitable: High reproducible MALDI MSI methods need to be combined 
with the expertise of pathologist to gain high-quality clinical studies.  
It was the second aim of this work to develop scores to assess repeatability and 
homogeneity, which are easy to compute, so scientists would be able to apply those 
without high computational effort during method development and as quality control. 
By using the scores natFC and R2 the best repeatable and homogeneous method for 
FFPE tissue analysis was identified and presented a start for further reproducibility and 
method optimisation studies. Entering the field of FFPE tissue analysis opens a door 
to countless tissue amounts of the last decades stored in clinics. 
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7 SUMMARY 
The enzyme class of proteases which hydrolyse proteins peptide bonds play a major 
role in tumour angiogenesis, invasion, and metastasis. Much effort was spent on the 
development of optical probes, in particular the use of fluorescently labelled probes. 
Although those probes can be administered in vivo and in vitro, there was only little 
research dealing with the topical application on frozen tissue slices. The design of 
photometric probes is challenging as it requires knowledge of the molecular target and 
chemical design to guarantee biocompatibility and specificity. Matrix-assisted laser 
desorption/ionization (MALDI) mass spectrometry imaging (MSI) comprises the 
advantages of mass spectrometry (the measure of mass-to-charge ratio m/z) with 
histological information. Several molecular classes like proteins, peptides, and lipids 
were measured with MALDI MSI in a spatially resolved way, but it was so far it has not 
been shown if tumour protease activity can be measured.  
Therefore, this thesis had thus the following aims: 
(1) To develop a method using MALDI MSI for monitoring tissue protease activity 
exemplarily on different porcine tissues. 
(2) To validate the developed method by time- and concentration-dependency, as 
well as by the production of specific degradation products. Further, to compare 
protease activities of tumorous and non-tumourous tissue in a gastric tumour 
mouse model. 
(3) To demonstrate the transferability of the developed MALDI MSI method to 
relevant clinical samples by analysing the proteolytic activity of human tissue 
biopsies from gastroscopy. 
At the beginning a substrate application method was developed that fulfilled the 
requirements of a homogeneous application and minimised delocalisation. With that 
method porcine tissue was analysed for proteolytic activity on the tracer substance P, 
which was chosen as a universal protease substrate. A time course study covering six 
hours revealed the time-dependent decrease of the substance P signal with the fastest 
degradation in porcine pancreas tissue and no degradation in porcine muscle tissue. 
By applying a protease inhibitor mix the degradation process was decelerated to 
different extents in the tissues. Porcine pancreatic tissue proteases showed less 
inhibitory response than porcine liver tissue. In addition to the decrease of the 
substance P m/z value, a number of C-terminally cleaved peptides arose during the 
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incubation. Those peptides might result from the activity of exopeptidases and were 
transiently formed. In the next step, the method was used to visualise proteolytic 
activity in mouse stomachs developing a spontaneous gastric tumour. The degradation 
of substance P was indeed faster, thus the proteolytic activity was higher, in the tumour 
compared to the surrounding tissue. Here again the application of the protease inhibitor 
mix decelerated the reduction of the substance P signal and the production of the 
related proteolytic products. With the use of MALDI Fourier-transform ion cyclotron 
resonance (FT-ICR) MSI the segmentation of the tissue in tumorous and non-
tumourous tissue based on the lipid tumour marker PC(34:1) + K+ correlated well with 
the hematoxylin-eosin staining and its pathological annotation. Further analysis of 
human gastric tumour biopsies showed the applicability of the method, but lacked in 
significant evidence, as only samples of two patients were analysed. Nevertheless, it 
already showed the importance of good cooperation between the surgeon, pathologist, 
and mass spectrometrist to ensure a representative sample cohort. Although further 
validation for visualisation of specific proteolytic activity will be necessary, this method 
has high potential for being a successful application in pre-clinical studies.  
To implement a MALDI MSI method in clinical routine a high degree of standardisation 
and reproducibility is required.  
Therefore further aims for this study were defined: 
(1) To develop scores suitable for standardisation (unbiased, low computational 
effort) of on-tissue digestion workflow for MALDI MSI by the use of clinical 
material processed methods already published. 
(2) To detect the best on-tissue digestion method for FFPE tissue and MALDI MSI 
in terms of repeatability and homogeneity of the application system. 
The best repeatable and homogeneous application has been identified by developing 
the natFC score and the R2 in mean- and pixel-wise-comparison of FFPE on-tissue 
digest preparation methods. The significant difference between the best method and 
the others was the prolonged incubation time of 18 hours. In summary, additional 
studies covering reproducibility and standardised MALDI MS methods with score base 
evaluation and a multicenter set-up are required to gain acceptance of this technology 
in clinical application.  
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